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CHAPTER 1 
General introduction and outline of the thesis 
 
Since its first description, invasive coronary angiography has been 
uniformly accepted to define the presence and extent of obstructive 
coronary artery disease (CAD), and to guide revascularization(1). However 
coronary angiography produces 2-dimensional silhouette images of the 3-
dimensional vascular lumen. Because angiographic stenosis severity is 
reported as a ratio of the stenosis’ minimal lumen diameter to the adjacent 
“normal” reference segment, accuracy is limited by the inability to identify 
both “diseased” and “normal” vessel segments, particularly in the setting of 
diffuse CAD. Additional artifacts including contrast streaming, branch 
overlap, vessel foreshortening, calcifications, and ostial origins further 
contribute to the uncertainty of the angiographic interpretation of coronary 
stenosis severity. Despite numerous attempts to evaluate complex 
anatomy, the angiographer is still confronted with a visual dilemma in 
which no single view, or even multiple views, provides an answer. 
Considering these limitations, coronary anatomy alone, even with the 
highest resolution and a perfect repeatability, will never be sufficient to 
predict physiological behaviour of a single stenosis(2,3), particularly for those 
between 30% and 80% diameter stenosis(4-6). The main unknowns are the 
myocardial mass depending from the stenotic segment and the 
microvascular function. Both will determine maximal myocardial blood. 
In contrast fractional flow reserve (FFR) is a flow index, defined as the ratio 
of maximal hyperemic myocardial blood flow in the presence of a stenosis 
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to the physiologic maximal hyperemic myocardial blood flow in the same 
territory but in the absence of any stenosis(7-9). As such, its value is 
influenced and integrates hyperaemic flow, which itself depends on 
stenosis severity, myocardial mass, and its microvascular function. Since 
mass and microvascular function are not likely to change in a given patients 
before and after revascularization, FFR indicates to what extent hyperaemic 
myocardial flow will increase after percutaneous coronary intervention 
(PCI) (i.e. normalization of the epicardial resistance)(10,11). FFR overcomes 
the visual-functional mismatch and stands alone in measuring ischemia in 
the catheterization laboratory with validated and durable clinical data 
supporting its use for predicting outcomes. Fifteen-year outcome data from 
the DEFER (Deferral vs. performance of percutaneous coronary intervention 
of functionally nonsignificant coronary stenosis) study demonstrate that 
postponing PCI in vessels with an FFR >0.75 is safe and associated with a 
low rate of clinical endpoints(12), whereas the FAME-2 (Fractional Flow 
Reserve versus Angiography for Multivessel Evaluation-2) study, among 
others, showed that patients with an abnormal FFR (i.e., lesion-specific 
ischemia) benefit more from revascularization than continued optimal 
medical therapy(13-15).  
Faced with this scenario, the almost systematic use of FFR in catheterization 
laboratory in different anatomical settings would seem almost intuitive and 
obvious, especially if we consider the clear indications of the European and 
American guidelines on myocardial revascularization(16,17). Nevertheless, the 
penetration of physiology-based guidance varies significantly across 
continents, countries, centers, and operators, ranging from 3% to 30% of 
the total volume of coronary revascularizations. Several factors have been 
proposed to explain the variability in FFR assessment adoption, such as 
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differences in equipment, reimbursement policies, and operator choice. 
Other investigators have suggested concerns regarding adenosine side 
effects, costs, and time(18,19). Therefore, the ability to derive FFR values from 
routinely performed coronary angiograms, without the need for a pressure 
guidewire or hyperemic stimulus, could have an important impact on daily 
clinical practice by streamlining the workflow within the catheterization 
laboratory and avoiding the need for invasive coronary measurements. 
Several image-based FFR methodologies have recently been introduced. In 
this thesis we report the first multicenter validation studies of the two 
angiography derived-FFR technologies that are gaining ground in 
interventional cardiology practice: FFRangio and QFR. 
It is unclear whether FFR can predict which patients will actually have an 
increase in myocardial perfusion after PCI(20). Although the goal of PCI is to 
increase coronary blood flow by relieving epicardial coronary stenosis, early 
explorations showed that successful stenting increased coronary flow 
reserve (CFR) in only 80% of patients(21). This surprising failure to normalize 
CFR in all PCI patients was attributed to a combination of diffuse 
downstream atherosclerosis, or acutely induced or preexisting 
microvascular dysfunction. Microvascular dysfunction alone can cause 
ischemic symptoms in the absence of epicardial obstruction(22-24) and 
probably contributes to persistent ischemia despite successful 
revascularization(25). However, use of CFR to assess the microcirculation 
independently is limited in that CFR interrogates the flow status of both the 
epicardial artery and the microcirculation. Also the dependence on resting 
haemodynamics is an important theoretical limitation for the use of CFR as 
a primary diagnostic tool in ischemic heart disease(26,27).  
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In this sense, Fearon WF et colleagues setted up a novel index of 
microcirculatory resistance (IMR), defined as distal coronary pressure 
divided by the inverse of the hyperemic mean transit time (a correlate to 
absolute flow), measured simultaneously with the coronary pressure 
wire(28-32). The advantages of IMR include that is relatively easy to measure 
and can be performed simultaneously while measuring FFR without any 
extra equipment, is specific for the microvasculature and is independent 
from the hemodynamic variability(33-35). Still, it is not known whether 
therapeutic reduction of IMR (e.g. with an intracoronary vasodilator) 
confers clinical benefits. Nor is it known whether, in patient with stable 
CAD, treatment decisions based on an IMR threshold might have prognostic 
benefits (as has been shown to be the case with FFR). Also during IMR 
assessment an intrinsic variability of resting mean transit time (Tmnrest) of 7-
10%, and Tmnhyp of 4-8% have been reported.  
With this in mind, aiming to a quantitative assessment of the 
microcirculation independent of operators and the presence of epicardial 
stenoses, a recent development of a dedicated monorail infusion catheter 
(Rayflow™, Hexacath, Paris, France) has simplified the measurement of 
absolute coronary flow (Q) and microvascular resistance (R) in the cathlab, 
opening a new window to the coronary microcirculation. The present 
method relies on a simple basic principle. Three parameters should be 
known: the infusion rate of saline (in mL/min), the temperature of the 
saline when it enters the coronary tree (in degrees), and the temperature of 
the blood when saline and blood have been mixed in the distal part of the 
artery (in degrees). This rule of three allows the calculation of absolute Q(36). 
The calculated flow is hyperemic flow because it has been shown that the 
infusion of saline at room temperature through the RayFlow catheter 
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reliably uniformly induces maximal hyperemia(37). A major advantage of this 
method is that—in contrast to Doppler or index of microcirculatory 
resistance—it is completely operator independent. The saline infusion can 
be continued until a true steady state is achieved (typically within 10–15 
seconds), and during the entire measurement sequence, the operator does 
not touch the patient nor any catheter. In this thesis we report the fist 
study aimed at investigate feasibility, safety, and reproducibility of 
catheter-based measurements of absolute coronary blood flow and 
microvascular resistance.  
Outline of the thesis 
The thesis is divided in seven part: 
Part I. From pressure derived-FFR to Absolute Flow and Microvascular 
Resistance. In the first part of the thesis we report our research projects 
published in the field of coronary physiology, describing the gradual shift of 
attention over the years from the FFR measurements to the direct 
assessment of absolute coronary blood flow and microvascular resistance. 
The “leitmotiv” of this paradigm shift is represented by the research 
projects, presented in this section, regarding the agents inducing maximal 
hyperemia, starting from the intracoronary administration of adenosine to 
the intracoronary infusion of saline at room temperature through the 
Rayflow™ catheter.  
 
Part II. Fractional flow reserve and natural history of stable coronary 
artery disease. In the second part of the thesis we report the cluster of 
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research projects that focuses on the importance of FFR assessment of 
epicardial stenosis in patients with stable CAD, with both single vessels 
disease (chapter 7) and multivessel disease (chapter 9), underlining its 
prognostic value.   
 
Part III. Fractional flow reserve in special clinical settings. This section of 
the thesis is a collection of our research projects aimed at investigate the 
role of invasive functional assessment in patients in whom coronary artery 
bypass graft (CABG) is indicated, which already underwent CABG and in 
patients with left ventricular dysfunction (LVD) and/or heart failure (HF). 
We also provide a description of the impact on clinical decision making of 
guiding catheter disengagement during FFR assessment of intermediate 
coronary stenoses (chapter 11) and the FFR measurements in symptomatic 
patients with Myocardial Bridge (chapter 12). 
 
Part IV. Angiography-derived FFR technologies. We report in these 
sections the first-in man validations studies of the two main technologies in 
the field of angiography-derived FFR: FFRangio and QFR.  
 
Part V. Platelet and microvascular function. This part of the thesis is a 
collection of research projects aimed to evaluate the microvascular 
dysfunction with IMR in patients with stable CAD undergoing elective PCI. 
We investigated a) the protective rule of prasugrel vs. clopidogrel on 
microcirculation (chapter 24) b) the effect of G894T polymorphism on 
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residual platelet reactivity and on the risk of periprocedural myocardial 
infarction (PMI) (chapter 25); c) the impact of serum uric acid levels on high 
residual platelet reactivity after PCI (chapter 26); d) the procedure related 
microvascular activation in long lesions treated with bioresorbable vascular 
scaffold versus everolimus-eluting stent implantation (chapter 27). 
 
Part VI: Percutaneous coronary interventions in bifurcation lesions: from 
bench tests to clinical outcome. This section of the thesis focuses on the 
topic of PCI in bifurcation lesions. Regarding the bench tests, we describe 
the procedural steps in vitro of the reversed single string technique 
(chapter 29) and we report the validation of resorbable magnesium scaffold 
(RMS) in various non-bifurcation and bifurcation anatomies using standard 
interventional techniques (chapter 30). Concerning the clinical evaluation, 
we describe the clinical applicability of the single-string bifurcation stenting 
technique (chapter 28) and we report the results of the P2BiTO registry, 
regarding the major clinical, anatomic and procedural determinants of mid-
term clinical outcomes in all comer patient population undergoing PCI in 
bifurcations (chapter 31). 
 
Part VII: Discussion and conclusions. The last section of the thesis is a 
broad discussion of the addressed topics with the conclusions.   
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Part I 
 
From pressure derived-FFR to Absolute Flow 
and Microvascular Resistance  
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CHAPTER 2  
Standardization of Fractional Flow Reserve Measurements 
 
To assess the contribution of a new diagnostic test, a hierarchical 
model of efficacy was proposed by Fryback and Thornbury. Although the 
model was developed for the evaluation of diagnostic imaging, its 
parameters also apply to “physiological imaging,” with its attributes of: 1) 
technical quality; 2) diagnostic accuracy; 3) diagnostic thinking efficacy; 4) 
effect on therapy; 5) patient’s outcome; and 6) economic aspects (Figure 1). 
A key feature of this model is that for a test to be efficacious at a higher 
level in this hierarchy, it must be efficacious at lower levels. 
 
Figure 1: Fractional Flow Reserve: example of simultaneous DICOM format storage of 
complete physiological and angiographic information. Archiving this information (as well as 
intravascular ultrasound and optical coherence tomography, when available) side-by-side, in 
a format that is easily accessible (“same place, same time” principle) enables surgeons, 
interventional cardiologists, clinicians, and heart team meeting participants to be exposed to 
these different imaging modalities and to integrate “anatomy” and “physiology” into 
individual clinical decision making. CRA: cranial; DICOM: digital imaging and communications 
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in medicine; ECG: electrocardiogram; FFR: fractional flow reserve; LAO: left anterior oblique; 
Pa: aortic pressure; Pd: distal coronary pressure. 
Since the first description of pressure wire-based FFR, an 
abundance of data pertaining to each of these criteria have been reported. 
Accordingly, FFR is now considered to be the reference standard for the 
evaluation of the ischemic potential and the expected benefit from 
revascularization of coronary stenosis. Moreover, FFR is increasingly being 
used in clinical trials as an inclusion criterion or as an endpoint and to 
validate new diagnostic modalities. Although all major outcomes-
randomized clinical trials (RCTs) have made decisions on the basis of 
operator-derived FFR values, a handful of recent diagnostic accuracy 
studies sent tracings to physiology core laboratories for post hoc analysis. 
However, no matter where analysis takes place, technical or operator-
related artifacts in pressure recordings should be avoided, minimized, or at 
least identified if they occur.  
FFR is calculated from distal coronary pressure (Pd) and aortic 
pressure (Pa) obtained during maximal coronary hyperemia. In principle, 
these measurements are straightforward and almost fully automated, as 
illustrated in Figure 2. Yet, minor differences among practices of different 
laboratories have led to some heterogeneity in acquiring and interpreting 
the data. Because FFR-based decisions are important for patients’ 
outcomes, and given the need for rigor and reproducibility in reading the 
tracings by core laboratories, the highest technical quality of FFR 
measurements is desirable. As FFR by itself is a highly reproducible 
diagnostic measure, deviations mainly derive from a lack of standardization. 
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Figure 2: Typical example of FFR measurement obtained after intracoronary bolus injection 
of adenosine. The injection of the bolus is brief so that the aortic signal (red) is interrupted 
during no longer than 1 to 2 s. Automated calculation of FFR corresponds to the ratio of 
mean distal coronary pressure (green) to mean aortic pressure during maximal hyperemia. 
CRA: cranial; FFR: fractional flow reserve; LAO: left anterior oblique; Pa: aortic pressure; Pd: 
distal coronary pressure. 
 
Accordingly, this document proposes a standardized way of 
acquiring, recording, interpreting, and storing the pressure tracings for daily 
practice and for the purpose of clinical research through a core laboratory. 
Comprehensive reviews of the principle of FFR and of the FFR-based clinical 
outcome data have been described previously. 
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CHAPTER 3  
Intracoronary Adenosine: Dose-Response Relationship 
With Hyperemia 
 
The present study sought to establish the dosage of intracoronary 
(IC) adenosine associated with minimal side effects and above which no 
further increase in flow can be expected.  
Background: Despite the widespread adoption of IC adenosine in clinical 
practice, no wide-ranging, dose-response study has been conducted. A 
recurring debate still exists regarding its optimal dose.  
Methods: In 30 patients, Doppler-derived flow velocity measurements were 
obtained in 10 right coronary arteries (RCAs) and 20 left coronary arteries 
(LCAs) free of stenoses >20% in diameter. Flow velocity was measured at 
baseline and after 8 ml bolus administrations of arterial blood, saline, 
contrast medium, and 9 escalating doses of adenosine (4 to 500 µg). The 
hyperemic value was expressed in percent of the maximum flow velocity 
reached in a given artery (Q/Qmax, %).  
Results: Q/Qmax did not increase significantly beyond dosages of 60 mg for 
the RCA and 160 mg for LCA. Heart rate did not change, whereas mean 
arterial blood pressure decreased by a maximum of 7% (p < 0.05) after 
bolus injections of intracoronary (IC) adenosine. The incidence of transient 
A-V blocks was 40% after injection of 100 µg in the RCA and was 15% after 
injection of 200 µg in the LCA. The duration of the plateau reached 12 13 s 
after injection of 100 µg in the RCA and 21 6 s after the injection of 200 µg 
in the LCA. A progressive prolongation of the time needed to return to 
19 
 
baseline was observed. Hyperemic response after injection of 8 ml of 
contrast medium reached 65 36% of that achieved after injection of 200 µg 
of adenosine (Figure 3). 
 
Figure 3: Intracoronary adenosine dose-flow relationship. (Top) Dose-response data for the 
right coronary artery (RCA) (left panel) and the left coronary artery (LCA) (right panel). The 
data are expressed as the percent of maximum for each patient (Q/Qmax) at each dose of 
intracoronary (IC) adenosine. The error bars represent the 95% confidence intervals for each 
value. (Bottom) The bars represent the percent of patients in whom high-grade 
atrioventricular (AV) block occurred with that dose of adenosine. BL: baseline. 
 
Conclusions: This wide-ranging, dose-response study indicates that an IC 
adenosine bolus injection of 100 µg in the RCA and 200 µg in the LCA 
induces maximum hyperemia while being associated with minimal side 
effects. 
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CHAPTER 4  
Saline-Induced Coronary Hyperemia: Mechanisms and 
Effects on Left Ventricular Function 
 
Background: reliable method to assess volumetric maximal myocardial flow 
and absolute minimal microvascular resistance has been described almost 
10 years ago. The method is based on the principle of coronary 
thermodilution by continuous infusion of saline at room temperature 
during steady-state hyperemia. One of the prerequisites of the 
thermodilution principle is the complete and instantaneous mixing of the 
indicator, in this case saline at room temperature. Yet, the method was 
hampered by technical difficulties that precluded routine application. The 
technique was recently simplified by the development of a dedicated rapid 
exchange infusion catheter and a dedicated software allowing 
instantaneous calculation of volumetric flow and resistance. The present 
work is based on an incidental observation. While performing 
measurements of minimal microvascular resistance in patients with mild 
atherosclerosis, we observed the occurrence or the increase of a pressure 
gradient between the coronary ostium and the distal part of the coronary 
artery few seconds after the start of the intracoronary infusion of saline, 
even before the start of adenosine infusion (Figure 4). This observation 
suggested that the infusion of saline at room temperature could elicit 
coronary hyperemia. If infusion of saline would indeed induce maximal 
steady-state hyperemia, this would further simplify the application of 
coronary thermodilution-derived quantification of myocardial flow and 
resistance. 
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Figure 4. Example of simultaneous pressure and temperature recording in the left anterior 
descending coronary artery with mild diffuse atherosclerosis. A, Complete tracing of 
thermodilution-derived absolute flow measurements, including the moderate decline in 
coronary temperature (T) and the sharp decrease in temperature when the sensor is pulled 
back in the infusion catheter to assess the temperature of the saline when it enters the 
coronary artery (Ti). B, Magnification of the rectangle delineated in A by a white broken line. 
Approximately 10 s after the start of the infusion of saline at room temperature at the rate 
of 20 mL/min (yellow arrow), the distal temperature starts to decline, reaching a plateau 
after ≈20 s. This decrease in temperature is paralleled by an increase in pressure gradient 
across the mild epicardial stenosis suggesting the occurrence of hyperemia. FFR indicates 
fractional flow reserve. 
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Aim: This study was designed to study the effects of intracoronary infusion 
of saline at room temperature on the coronary circulation and myocardial 
function in humans and to explore its mechanisms. 
Methods and Results: Thirty-three patients were studied; in 24 patients, 
intracoronary Doppler flow velocity measurements were performed at rest, 
after IC adenosine, and during increasing infusion rates of saline at room 
temperature through a dedicated catheter with 4 lateral side holes. In 9 
patients, global longitudinal strain and flow propagation velocity were 
assessed by transthoracic echocardiography (TTE) during a prolonged 
intracoronary saline infusion. Taking adenosine induced maximal hyperemia 
as reference, intracoronary infusion of saline at rates of 5, 10, 15, and 20 
mL/min induced 6%, 46%, 111%, and 112% of maximal hyperemia, 
respectively (Figure 5). There was a close agreement of maximal saline- and 
adenosine induced CFR (intraclass correlation coefficient, 0.922; P<0.001). 
The same infusion rates given through 1 end hole (n=6) or in the 
contralateral artery (n=6) did not induce a significant increase in flow 
velocity. Intracoronary saline given on top of an intravenous (IV) infusion of 
adenosine did not further increase flow. Intracoronary saline infusion did 
not affect blood pressure, systolic, or diastolic left ventricular function. 
Heart rate decreased by 15% during saline infusion (P=0.021). 
23 
 
 
Figure 5: Representative example of coronary flow velocity tracings at baseline and after an 
intracoronary bolus of 200 μg of adenosine, during infusion of saline at room temperature at 
rates of 5, 10, 15, and 20 mL/min. A, Saline is infused through the side holes of the catheter 
advanced over the Doppler wire. B, Saline is infused through the distal hole of the catheter 
advanced over the Doppler wire. C, Saline is infused through the side holes of an infusion 
catheter advanced in a contralateral artery. 
 
Conclusions: intracoronary infusion of saline at room temperature through 
a dedicated catheter for coronary thermodilution induces steady-state 
maximal hyperemia at a flow rate ≥15 mL/min. These findings open new 
possibilities to measure maximal absolute coronary blood flow and minimal 
microcirculatory resistance. 
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CHAPTER 5  
Reduced Coronary Flow Reserve in Coronary Arteries 
without Stenosis: Impact of Various Hemodynamic and 
Clinical Parameters 
 
Background: CFR, the ratio of hyperemic flow to baseline flow, was 
proposed over 40 years ago, and has been the gateway for clinical 
application of coronary physiology. This study aimed to evaluate the impact 
of various clinical and hemodynamic parameters on CFR in angiographically 
normal coronary arteries. 
Methods: In 30 patients with stable coronary artery disease, Doppler-
derived flow velocity measurements were obtained in angiographically 
normal coronary arteries. Flow velocity was measured during one minute 
under resting conditions and then after administering increasing dosages of 
IC adenosine boluses (4 to 500 μg).  
Results: In coronary arteries without significant stenosis, CFR varied from 
1.42 to 4.88  (average 2 .83±0.88).  Patients  were  categorized  into  two  
groups using the median CFR: low CFR ranging from 1.42 to 2.78 and high 
CFR ranging from 2.87 to 4.88. Baseline flow velocity was significantly 
higher in patients with low CFR than in patients with high CFR. Hyperemic 
flow velocity was similar in both groups (Figure 6).  
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Figure 6: Baseline and hyperemic flow in the two groups. 
 
Baseline flow velocity showed a significant correlation with the absolute 
value of CFR (R2=0.42, p<0.01), while hyperemic flow did not correlate with 
it (R2=0.04, p=0.30). A trend was observed such that, in patients with low 
CFR, less adenosine was needed to reach maximal hyperemia. No difference 
was found in any other hemodynamic or clinical or parameters between 
groups. 
Conclusions: In coronary arteries free from significant stenosis, "resting" 
flow velocity appears to be a major determinant of pathologic CFR, more so 
than hyperemic flow. 
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CHAPTER 6  
Catheter-Based Measurements of Absolute Coronary 
Blood Flow and Microvascular Resistance: Feasibility, 
Safety, and Reproducibility in Humans 
 
Background: The principle of continuous thermodilution can be used to 
calculate absolute coronary blood flow (Q). The concomitant measurement 
of pressure in the distal part of the vessel allows the calculation of 
myocardial resistance. The recent development of a dedicated monorail 
infusion catheter has simplified the measurement of absolute Q and 
microvascular resistance (R) in the cathlab, opening a new window to the 
coronary microcirculation. Q (mL/min) can be calculated by continuous 
intracoronary infusion of saline, as previously described, according to the 
equation 
      
       
      
         
where Qi is the saline infusion rate in mL/min, Tb is the temperature of 
blood in the distal coronary before infusion of saline, Ti is the temperature 
of the infused saline when it exits the infusion catheter, and T is the 
temperature of the homogenous mixture of blood and saline in the distal 
part of the coronary artery during infusion. The constant cp relates to the 
difference between the specific temperature and density of blood and 
saline, and when saline is infused in blood, this is equal to 1.08. In practice, 
the temperature of blood (Tb, ≈37°C) is taken as a reference, and the other 
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temperatures are measured with respect to that value. Therefore, Ti and T 
stand for relative temperatures compared with Tb, and the equation is 
simplified as follows: 
       
  
 
          
Since, in clinical practice, Qi is chosen between 15 and 30 ml/min, the last 
part of the equation subtracts between 1.2 and 2.4 mL/min from the 
calculated coronary blood flow and can therefore be neglected. 
Consequently, the equation is further simplified to: 
       
  
 
   
Absolute microvascular resistance (R) is calculated in analogy to Ohm’s law: 
      
  
  
   
where Pd is the distal coronary pressure and Qb is the coronary blood flow. 
Aim: Although data on the in vitro validation of the method and the 
infusion catheter have been recently published, in vivo data are lacking. The 
aim of the study is to explore the safety, feasibility, and reproducibility of 
coronary blood flow and R measurements as measured by continuous 
thermodilution in humans. 
Methods and Results: Absolute coronary flow and R can be calculated by 
thermodilution by infusing saline at room temperature through a dedicated 
monorail catheter. The temperature of saline as it enters the vessel, the 
temperature of blood and saline mixed in the distal part of the vessel, and 
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the distal coronary pressure were measured by a pressure/temperature 
sensor-tipped guidewire (Figure 7).  
 
Figure 7: Thermodilution-derived absolute coronary blood flow and microvascular resistance 
measurement. Example of thermodilutionderived absolute microvascular resistance and 
coronary blood flow in a left anterior descending artery. The flow rate of the administered 
saline is 20 mL/min, and the calculated values of absolute coronary blood flow (Q) and 
microvascular resistance (R) are 0.146 L/min and 622 mm Hg/L/min, respectively. The 
theoretically achieved maximum blood flow in the absence of epicardial stenoses (Qnorm), 
that is, if fractional flow reserve (FFR) was equal to 1, is also displayed. Pa indicates aortic 
pressure; and Pd, distal coronary pressure. 
The feasibility and safety of the method were tested in 135 patients who 
were referred for coronary angiography. No significant adverse events were 
observed; in 11 (8.1%) patients, bradycardia and concomitant 
atrioventricular block appeared transiently and were reversed immediately 
on interruption of the infusion. The reproducibility of measurements was 
tested in a subgroup of 80 patients (129 arteries). Duplicate measurements 
had a strong correlation both for coronary blood flow (ρ=0.841, P<0.001; 
intraclass correlation coefficient=0.89, P<0.001) and R (ρ=0.780, P<0.001; 
intraclass correlation coefficient=0.89, P<0.001). In Bland–Altman plots, 
there was no significant bias or asymmetry. 
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Conclusions: Despite some limitations, the present data confirm the 
feasibility, safety, and reproducibility of thermodilution-derived hyperemic 
coronary flow (expressed in L/min) and of coronary R measurements 
(expressed in mm Hg/L/min or Wood units) that can be performed simply 
and easily. If further confirmed and validated, this approach should allow a 
more quantitative and operator-independent quantification of the 
microvasculature and help in assessing treatment of microvascular 
dysfunction. 
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Part II 
 
Fractional flow reserve and natural history of 
stable coronary artery disease  
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CHAPTER 7  
Significance of Intermediate Values of Fractional Flow 
Reserve in Patients With Coronary Artery Disease 
 
Background: FFR represents the standard of reference for invasive 
functional evaluation of the ischemic potential of coronary stenosis and is a 
valuable tool to guide percutaneous revascularization. An FFR value ≤0.75 is 
almost uniformly associated with signs of ischemia, whereas an FFR >0.80 is 
usually associated with the absence of ischemia. Based on numerous 
randomized trials and registries in most subsets of lesions and patients, the 
threshold value of 0.80 has been widely accepted to guide clinical decision 
making. The best treatment strategy for intermediate stenosis with FFR in 
the narrow gray zone of values, that is, between 0.76 and 0.80, has been 
questioned. Therefore, we analyzed the long-term clinical outcome of 
patients with an isolated stenosis within the gray zone (0.76–0.80) or 
immediately next to the gray zone (0.70–0.75 and 0.81–0.85). 
Methods and Results: From February 1997 to June 2013, all patients with 
single-segment disease and an FFR value within the gray zone or within the 
2 neighboring FFR strata (0.70–0.75 and 0.81–0.85) were included. Study 
end points consisted of major adverse cardiovascular events (death, 
myocardial infarction, and any revascularization) up to 5 years. Of 17 380 
FFR measurements, 1459 patients were included. Of them, 449 patients 
were treated with revascularization and 1010 patients were treated with 
medical therapy (Figure 8). In the gray zone, the major adverse 
cardiovascular events rate was similar (37 [13.9%] versus 21 [11.2%], 
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respectively; P=0.3) between medical therapy and revascularization, 
whereas a strong trend toward a higher rate of death or myocardial 
infarction (MI) (25 [9.4] versus 9 [4.8], P=0.06) and overall death (20 [7.5] 
versus 6 [3.2], P=0.059) was observed in the medical therapy group (Figure 
8). Among medical therapy patients, a significant step-up increase in major 
adverse cardiovascular events rate was observed across the 3 FFR strata, 
especially with proximal lesion location. In revascularization patients, the 
major adverse cardiovascular events rate was not different across the 3 FFR 
strata (Figure 9). 
 
Figure 8: Cumulative rate (%) of MACE (log-rank, 0.87; P=0.3) and death or MI (log-rank, 
2.96; P=0.08) in the gray-zone patients treated with medical therapy or revascularization. 
MACE indicates major adverse cardiovascular event; MI, myocardial infarction; MT, medical 
therapy; and REV, revascularization. 
 
 
Figure 9: A) MACE-free survival (%) in patients of the medical therapy group stratified by FFR 
strata (log-rank, 15; P<0.001). B) MACE rate (%) in patients receiving medical therapy, 
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stratified according to the FFR strata, and grouped according to the location of the lesions 
(proximal vs distal). FFR indicates fractional flow reserve; and MACE, major adverse 
cardiovascular event. 
 
Conclusions: Patients with an isolated stenosis located in a proximal 
coronary segment and FFR within the gray zone of 0.76 to 0.80. 
demonstrate a clinical outcome that is suboptimal when deferred to 
medical therapy alone. These data confirm the value of the 0.80 FFR 
threshold, and favor a revascularization strategy of coronary stenoses with 
FFR ≤0.80.  
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CHAPTER 8  
Visual and Quantitative Assessment of Coronary Stenoses 
at Angiography Versus Fractional Flow Reserve: The 
Impact of Risk Factors 
 
Background: The correlation between angiographic assessment of coronary 
stenoses and FFR is weak. Whether and how risk factors impact the 
diagnostic accuracy of angiography is unknown. We sought to evaluate the 
diagnostic accuracy of angiography by visual estimation (VE) and by 
quantitative coronary angiography (QCA) when compared with FFR and 
evaluate the influence of risk factors (RF) on this accuracy. 
Methods and Results: In 1382 coronary stenoses (1104 patients), percent 
diameter stenosis by visual estimation (DSVE) and by quantitative coronary 
angiography (DSQCA) was compared with FFR. Patients were divided into 4 
subgroups, according to the presence of RFs, and the relationship between 
DSVE, DSQCA, and FFR was analyzed. Overall, DSVE was significantly higher 
than DSQCA (P<0.0001); nonetheless, when examined by strata of DS, DSVE 
was significantly smaller than DSQCA in mild stenoses, although the reverse 
held true for severe stenoses. Compared with FFR, a large scatter was 
observed for both DSVE and DSQCA. When using a dichotomous FFR value of 
0.80, C statistic was significantly higher for DSVE than for DSQCA (0.712 versus 
0.640, respectively; P<0.001). C statistics for DSVE decreased progressively 
as RFs accumulated (0.776 for ≤1 RF, 0.750 for 2 RFs, 0.713 for 3 RFs and 
0.627 for ≥4 RFs; P=0.0053) (Figure 10A). Also 97 (9%) patients had diabetes 
mellitus, and 1007 (91%) did not have diabetes mellitus. Both groups were 
similar in terms of baseline and angiographic characteristics, with the 
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exception of higher prevalence of dyslipidemia, family history of coronary 
artery disease, and higher body mass index in the diabetic group. FFR was 
significantly higher in the diabetic group compared with the nondiabetic 
group (0.83 [0.76, 0.90] versus 0.81 [0.73, 0.88]; P=0.013). In ROC analyses, 
the DSVE curve for the diabetic group had a lower C statistic compared with 
the nondiabetic group (0.524 versus 0.729; P<0.001;) (Figure 10B). 
 
Figure 10: A) Receiver operating characteristic curves for diameter stenosis by visual 
estimation (DSVE) according to the presence of risk factors. B) Receiver operating 
characteristic curves for DSVE in diabetic and nondiabetic patients. AUC indicates area under 
the curve. 
 
Conclusions: This study confirms the weak correlation between 
angiographic metrics and FFR and indicates that, despite its subjectivity, VE 
is more accurate in predicting physiology than QCA. The presence of risk 
factors markedly blur this relationship: the more risk factors, the weaker 
the potential of angiography to assess physiology, particularly so in 
diabetics. In these patients—even more than in others—a combined 
angiographic and functional approach is mandated for optimal clinical 
decision-making about revascularization. 
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CHAPTER 9  
Angiography versus hemodynamic assessment to predict 
the natural history of coronary stenoses: a fractional flow 
reserve versus angiography in multivessel evaluation 2 
(FAME 2) substudy 
 
Background: FFR has become the standard of reference for the invasive 
evaluation of coronary stenosis. Nevertheless, interventional cardiologists 
still prefer angiography for guiding decision making about revascularization, 
even in the absence of any budget and logistic constraints. The 
angiographic thresholds of 50% or 70% diameter stenosis (DS) are still used 
to define obstructive coronary artery disease to risk stratify patients, justify 
revascularization, serve as an end point in studies on revascularization 
strategies, and validate other approaches. Accordingly, we investigated the 
spontaneous, vessel-oriented clinical outcome of patients from the FAME 2 
trial (Fractional Flow Reserve Versus Angiography in Multivessel Evaluation 
2) in whom no revascularization was performed but in whom both the DS 
and functional (FFR) severity was known. The aim of the study was to 
compare the accuracy of both approaches in predicting the natural history 
of CAD. 
Methods: The present analysis included the 607 patients from the FAME 2 
trial in whom no revascularization was performed. FFR varied from 0.20 to 
1.00 (average 0.74±0.16), and DS (by quantitative coronary analysis) varied 
from 8% to 98% (average 53±15). The primary end point, defined as vessel-
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oriented clinical end point (VOCE) at 2 years, was a composite of 
prospectively adjudicated cardiac death, vessel-related MI, vessel-related 
urgent, and not urgent revascularization. The stenoses were divided into 4 
groups according to FFR and DS% values: positive concordance (PC) 
(FFR≤0.80; DS≥50%), negative concordance (NC) (FFR>0.80; DS<50%), 
positive mismatch (PM) (FFR≤0.80; DS<50%), and negative mismatch (NM) 
(FFR>0.80; DS≥50%). 
Results: Clinical 2-year follow-up was available for all patients. Overall, 
VOCEs occurred in 26% of cases. The rate of VOCE was highest in the group 
of stenoses with PC (FFR ≤0.80; DS ≥50%; 125/317 lesions [39.4%]) and 
lowest in stenoses with an NC (FFR >0.80; DS <50%; 17/216 lesions [7.9%]). 
The rate of VOCEs was similar in stenoses with a PM (FFR ≤0.80; DS <50%) 
and with a PC (50/153 lesions [32.7%] versus 125/317 lesions [39.4%], 
respectively; P=0.139). In contrast, the rate of VOCEs of stenoses with a NM 
(FFR >0.80; DS ≥50%) was lower as compared with stenoses with a PM 
(16/113 lesions [14.2%] 50/153 lesions [32.7%], respectively; P=0.001) but 
was not significantly different compared with stenoses with an NC (17/216 
[7.9%]; P=0.099). There was no significant difference in terms of lesion-
related outcome between the NM (FFR >0.80; DS ≥50%) and the NC (FFR 
>0.80; DS <50%), although there was a trend (P=0.099) (Figure 11). 
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Figure 11: Kaplan‒Meier survival curve of 4 groups according to the values of fractional flow 
reserve (FFR) and percent diameter stenosis (DS). CI indicates confidence interval; HR, 
hazard ratio; and VOCE, vessel-oriented clinical end point. Red, positive concordance 
(FFR≤0.80; DS≥50%); blue, negative concordance (FFR>0.80; DS<50%); orange, positive 
mismatch (FFR≤0.80; DS<50%); and green, negative mismatch (FFR>0.80; DS ≥50%). 
 
 When the angiographic cutoff was set at 70% DS, the outcome results did 
not change. The rate of VOCE over time was significantly larger when 
lesions have a DS ≥50% or when lesions have an FFR ≤0.80, but the 
difference between the event curves was markedly larger for FFR than for 
DS (Figure 12). At the univariable analysis of predictors of VOCE the global 
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SYNTAX score was not found to be a significant predictor for vessel-related 
outcome. Moreover at the multivariable analysis FFR ≤0.80 was associated 
with a 4.16-fold increase in the hazard of VOCE and DS ≥50% with a 1.36-
fold increase. After introduction of an interaction term, FFR ≤0.80 was 
associated with a 7.28- fold increase in the hazard of VOCE during the first 
90 days and a 3.29-fold increase in the hazard of VOCE occurring >90 days.  
 
Figure 12: Kaplan‒Meier survival according to the values of percent diameter stenosis (DS) 
and fractional flow reserve (FFR). CI indicates confidence interval; HR, hazard ratio; N, 
number of events; and VOCE, vessel-oriented clinical end point. 
 
Conclusion: From this side-by-side comparison of DS and FFR to lesion-
related outcome, it appears that the main determinant of the natural 
history of a lesion is its hemodynamic significance rather than its 
angiographic appearance. DS is the cornerstone of the definition of CAD. 
Because clinical outcome is the ultimate validation test for any new 
treatment or metrics, the present findings suggest that FFR should replace 
the 50% DS criteria for the definition of obstructive CAD. 
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CHAPTER 10  
Coronary lesion progression as assessed by fractional flow 
reserve (FFR) and angiography 
 
Background: Intermediate coronary stenoses are prevalent in patients 
undergoing coronary angiography and are defined as a 30-70% luminal 
narrowing. Nevertheless, a heterogeneity exists in the definition of clinically 
significant coronary stenosis depending on diagnostic tool or location. This 
scatter in defining the significance of stenoses is attributed to the limited 
ability of anatomic tools to predict the functional impact of the lesions. 
Accordingly, guidelines recommend deferring revascularization with FFR > 
0.80, irrespective of location and angiographic appearance due to the very 
low event rates. This “watchful waiting” approach begs the question of how 
intermediate, non-revascularized lesions evolve over time, both 
anatomically and functionally. To date, there is an abundance of data 
regarding the anatomic progression of coronary lesions that has shaped our 
understanding of their natural history. Yet, no data exist regarding the 
longitudinal functional progression of the coronary stenoses assessed by 
FFR.  
Aim: To explore the evolution of coronary lesions that had repeated 
physiologic evaluation by FFR as an endpoint, describe the clinical 
significance of longitudinal FFR change (ΔFFR = FFRfollow-up – FFRbaseline), its 
correlation with angiographic indices and identify predictors of FFRfollow-up. 
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Methods and results: A retrospective, single-center analysis of 414 
stenoses (331 patients) with consecutive FFR measurements at least six 
months apart was performed [median time interval: 24 (17, 37) months]. 
The change in percent diameter stenosis was 2% (-5%, 11%). FFR values at 
baseline and follow-up were 0.86 (0.82, 0.90) and 0.83 (0.79, 0.90) 
respectively (<0.0001). The median ΔFFR was -0.007 (-0.028, 0.010) per 
year. A significant linear correlation of FFRfollow-up with FFRbaseline was noted 
(ρ= 0.550, P<0.0001); this was also the case on a per vessel analysis (Figure 
13).  
 
Figure 13: Scatterplot and correlations of FFR values at baseline and follow-up on a per 
vessel basis. The black line depict the 0.80 FFR threshold below which a lesion is clinically 
significant and should be revascularized. The red area includes lesions that were non-
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ischemic at baseline and became ischemic at follow-up (FFR deterioration); the opposite is 
true for lesions in the green area (FFR improvement). Non-parametric Sperarman’s ρ 
correlation coefficients are presented. FFR= fractional flow reserve.  
  
Similar results were noted for DS% and MLD, while lower values at follow-
up (P<0.0001 for both the Wilcoxon matched-pairs test and the mixed 
effects repeated measures model), while RD remained unchanged. Rates of 
change for %DS was 1 (-2, 5) % and for MLD –0.012 (-0.175, 0.080) 
mm/year. Worsening FFR (ΔFFR <-0.05) was observed in 105 (25%) 
stenoses, stable FFR (-0.05≤ΔFFR≤0.05) in 276 (67%) and improving FFR 
(ΔFFR>0.05) in 33 (8%) stenoses. The number of hemodynamically 
significant stenoses (FFR≤0.80) was higher at follow-up compared to 
baseline (33% versus 17%, P<0.0001); ΔFFR correlated weakly with delta 
diameter stenosis (Δ%DS, ρ=-0.111, P=0.024). FFR baseline and PCI between 
measurements at a non-index segment were independent predictors of FFR 
follow-up (R2=0.2301). In ROC analysis, FFR baseline values predicted future 
clinically significant values [c-statistic: 0.736 (95% CI: 0.682 – 0.783)].  
Conclusions: The findings of our study point to a slow progression rate for 
coronary atherosclerotic lesions, as evaluated by both angiography and FFR. 
Longitudinal data regarding FFR evolution are presented for the first time, 
with only 1 out of 4 lesions having a significant FFR worsening over a two-
year period. FFRbaseline, but not angiographic indices, is an independent 
predictor of longitudinal functional atherosclerosis progression, predicting 
which lesions will require revascularization. This finding can be clinically 
useful in the context of forgoing repeat angiographies for patients with 
persistent symptoms and high baseline FFR.   
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Part III 
 
Fractional flow reserve in special clinical 
settings  
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CHAPTER 11  
Detect  fractIonal flow reServe of Epicardial steNosis with 
Guiding cAtheter disenGagEment: DISENGAGE registry 
 
Background: The application of FFR in daily practice as well as for research 
purposes has been standardized in order to avoid technical or operator-
related artifacts in pressure recordings and interpretation. However the 
impact of guiding catheter (GC) at the level of the coronary ostium during 
FFR measurements of intermediate coronary stenoses has been poorly 
investigated up to date. The mere presence of a GC in the coronary ostium 
induces some degree of stenosis, which depends on the relative size of the 
GC and the coronary ostium. This results into a not fully hyperemic flow 
across the ostium, with an artificial decrease of the mean aortic pressure 
(Pa) and a final overestimation of FFR value (Figure 14).  
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Figure 14: A) impact of different size of GCs on the relative diameter of the coronary ostium, 
with and without stenosis; B) mechanism of artificial decrease of the mean aortic pressure 
(Pa) and a final overestimation of FFR value; C) Angiographic example of intermediate 
stenosis and D) the corresponding FFR measurements with GC ingaged and GC disengaged. 
GC= guiding catheter; FFR= fractional flow reserve; VE= visual estimation; DS= diameter 
stenosis; RVD= reference vessel diameter; MLD= minimal lumen diameter; LL= lesion length. 
 
Aim: In this prospective registry we aimed at investigate if the Δ FFRengaged – 
FFRdisengaged: (1) might be significantly different from the intrinsic variability 
of repeated FFR measurements; (2) could impact clinical decision making in 
intermediate coronary stenoses (e.g. changes on the FFR values from above 
0.80 to below 0.75 and/or below 0.80). Also we aimed to evaluate if (3) the 
GC disengagement might have a different impact on stenoses related to a 
large amount of myocardium as compare to those related to small amount 
of myocardium. 
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Methods: Between October 2015 and December 2016, FFR was 
prospectively measured in 202 intermediate isolated stenosis (DS 46±10%; 
MLD 1.6±0.4 mm; RVD 3.0±1.6 mm; LL 15±8 mm) of 173 patients with 
stable angina (93%), silent ischemia (5%), and acute coronary syndrome 
(ACS) (2%, in non-culprit lesion). Stenoses were located on left anterior 
descending artery (n=124), diagonal branch (n=3), left circumflex artery 
(n=28), obtuse marginal branch (n=14), intermediate branch (n=5) and right 
coronary artery (n=28). Patients with diffuse disease, tandem lesions, left 
main and aorto-ostial stenosis, and culprit lesions of ST-segment elevation 
myocardial infarction (STEMI) and non-ST segment elevation myocardial 
infarction (NSTEMI) were excluded. FFR were measured with a 0.014-inch 
pressure guidewire (Pressure Wire Certus, St. Jude Medical, St. Paul, MN, 
US) with IC adenosine at the dose of 100 µg for the RCA and 200 µg for the 
LCA. For each stenosis, FFR was measured twice: with the GC engaged 
(FFRengaged) and with the GC disengaged (FFRdisengaged). To assure the quality 
of the measurements, the equalization was checked with both GC engaged 
and disengaged, likewise the position of the wire was filmed to document 
the stability of the pressure sensor during the manipulation of the GC.  
Results: GC disengagement was associated with a slight albeit non-
significant decrease in FFR values overall (FFRengaged 0.84 ± 0.08 vs 
FFRdisengaged 0.80 ± 0.08; Δ FFRengaged–FFRdisengaged 0.04 ± 0.03; p= 0,92), mainly 
due to an increase of the mean Pa value (Pa engaged 78.7 ± 13.5 mmHg vs Pa 
disengaged 82.9 ± 13.6; p= 0,79) rather than changes in the mean Pd value (Pd 
engaged 66.3 ± 13 mmHg vs Pd disengaged 66.6 ± 13.2 mmHg; p= 0,86) (Figure 15). 
However in 38 stenoses (22% patients and 19% stenoses) whose FFR values 
were mostly located in the 0.81-0.85 stratum, GC disengagement was 
associated with a shift from above to below the clinical-decision making 
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threshold of 0.80. Also in 50% of the stenoses (102/202) ΔFFR was ≥ 0.04, 
which correspond to twice the value to be expected from repeated FFR 
measurements (test-retest repeatability of FFR; cut-off value: 0.02). GC 
disengagement had a significant impact on FFR measurements of stenoses 
related to large amount of myocardium as compare to those related to 
small amount of myocardium(∆FFRengaged–FFRdisengaged proximal and mid 
segments 0.043 ± 0.03 vs ∆FFRengaged–FFRdisengaged distal segments 0.029 ± 
0.03; p= 0.028) (Figure 16). 
 
Figure 15: A) Overall FFR values changes after GC disengagement; B) Pd and Pa changes after 
GC disengagement. GC indicates guiding catheter.  
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Figure 16: ∆FFRengaged–FFRdisengaged of stenoses related to large amount of myocardium 
(proximal and mid coronary segments) vs. stenoses related to small amount of myocardium 
(distal coronary segments or side branches).  
 
Conclusions: GC disengagement is associated with a slight albeit non-
significant decrease in FFR values overall. Yet, GC disengagement resulted 
into a shift of FFR values from above to below the clinical-decision making 
threshold of 0.80 in 1 out of 5 measurements. Therefore it might be 
advisable to reassess FFR after disengaging the GC in case of FFR values 
close to 0.80. 
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CHAPTER 12  
Angiographic and hemodynamic modifications of 
Myocardial Bridge during supine bicycle exercise 
 
Aim: The aim of this study is to evaluate the hemodynamic effect of 
physiological exercise during coronary angiogram with Pd/Pa, end diastolic 
Pd/Pa and FFR measurements in symptomatic patients with Myocardial 
Bridge (MB). 
Methods: We included all consecutive patients between July 2014 and 
November 2016 with symptomatic MB without significant CAD. Coronary 
angiogram was performed with radial approach and supine bicycle set on 
the table. A pressure wire was placed downstream the MB. Systolic 
compression was assessed with QCA. Hemodynamic was continuously 
recorded during the protocol with Pd/Pa and end diastolic Pd/Pa at rest and 
during exercise. The exercise protocol did not use nitrates prior to exercise, 
it started at 50 watts and increased of 15 watts every 2 minutes. After 
exercise intracoronary nitrates was used and finally IC adenosine 
administration for FFR measurement. The aim of this study is to evaluate 
the hemodynamic effect of physiological exercise on angiography, Pd/Pa, 
end diastolic Pd/Pa and FFR. 
Results: 9 symptomatic patients with an isolated MB were included. 
Patients reached in average 73%±10% of maximum heart rate. No 
complication occurs during this protocol. Compression during systole 
significantly increases in peak exercise compare to rest respectively 78% 
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versus 37% (p=0.003). However Pd/Pa and end diastolic Pd/Pa values did not 
significantly changed respectively 0.90 at rest versus 0.87 at peak exercise 
(p=0.21) and 0.85 versus 0.82 (p=0.35). During the protocol no significant 
difference was observe between rest, peak exercise Pd/Pa and after nitrates 
(p>0.05 for all). FFR was significantly lower compared to rest, peak exercise 
and after nitrates (p<0.05 for all). End diastolic Pd/Pa values did not differ 
significantly except after nitrates and when adding adenosine compared to 
rest, respectively 0.78±0.05, 0.77±0.05 and 0.85±0.06, p=0.038 and 
p=0.017). Post exercise FFR was significantly lower compared to rest Pd/Pa. 
Lowest values were observed with FFR with a significant decrease flow 
(p=0.02) while it is not the case when using end diastolic Pd/Pa (p=0.20) 
(Figure 17). 
 
Figure 17: Changes in Pd/Pa, End diastolic Pd/Pa and FFR at rest, peak exercise after nitrates 
and after IC adenosine administration. FFR= fractional flow reserve; IC= intracoronary.  
 
51 
 
Conclusions: We reported invasive hemodynamic assessment of MB during 
physiological exercise conditions with supine bicycle. MB increase systolic 
compression during exercise with a preserved hemodynamic indices. 
Invasive hemodynamic evaluation of MB might be better assessed with FFR 
at rest. 
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CHAPTER 13  
Fractional flow reserve to guide and to assess coronary 
artery bypass grafting 
 
The aim of this review is to highlight the role of invasive functional 
evaluation in patients in whom CABG is indicated, and to examine the 
clinical evidence available in favour of FFR adoption in these patients, 
outline appropriate use, as well as point out potential pitfalls. FFR after 
CABG will also be reviewed, highlighting its correct interpretation and 
adoption when applied to both native coronary arteries and bypass grafts 
(Figure 18). Practice European guidelines support the use of FFR to 
complement coronary angiography with the highest degree of 
recommendation (Class IA) for the assessment of coronary stenosis before 
undertaking myocardial revascularization when previous non-invasive 
functional evaluation is unavailable or not conclusive. As a result, FFR has 
been adopted in routine clinical practice to guide clinicians decision as to 
whether or not perform a revascularization. Of note, due to the increasing 
confidence of the interventional cardiologists, FFR guidance is also being 
implemented to indicate or guide CABG. This is in anticipation of supportive 
clear-cut evidence, since recommendations for FFR adoption were based on 
randomized clinical trials investigating PCI strategies in which patients with 
typical indications for CABG were excluded (e.g. left main disease, valvular 
disease, and coronary anatomy unsuitable for PCI). Based on the critical 
appraisal of the literature, FFR can play an important role in risk 
stratification and determining management strategy of patients either 
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before or after CABG. The available data are mostly observational and seem 
to support the reliability and prognostic role of FFR in these patients. While 
waiting for the results of ongoing RCTs, FFR can be used to guide 
revascularization strategies, taking into account the divergent visions of the 
cardiac surgeons who aim for once-in-a-lifetime treatment of the patients, 
and that of the interventional cardiologists who have the option of 
deferring percutaneous revascularization to a later stage. 
 
Figure 18: Schematic representation of a left coronary artery with sequential stenosis of the 
ostial left main (LM) and proximal left anterior descending (LAD) coronary artery (A, arrows). 
FFR of the LM measured with the pressure wire positioned in the left circumflex artery is 
0.84 (B). If the proximal LAD was stented, FFR of the LM would lower to 0.72 as a 
consequence of the significant increase in the subtended myocardial mass (C). If a bypass 
graft would be implanted distal to the LAD stenosis, FFR of the LM would either remain the 
same or slightly increase, as a consequence of the fact that a large part of the left coronary 
artery territory is now being perfused by another vascular conduit (D). FFR, fractional flow 
reserve. 
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Chapter 14 
Impact of fractional flow reserve on surgical coronary 
revascularization strategy 
 
Background: FFR during angiography is associated with hemodynamic 
reclassification of coronary disease severity with significant impact on 
revascularization strategies. However, no prospective data exist on the 
impact of FFR on surgical coronary revascularization strategies. 
Methods: GRAFFITI is a single-blinded, open-label, prospective 1:1 
randomized controlled multi-center pilot trial comparing FFR-guided versus 
angiography-guided CABG surgery. Patients with a significantly diseased left 
anterior descending or left main stem and at least one more major 
coronary artery with angiographically intermediate stenosis were enrolled 
in the trial. First surgeons made a pure angiography-guided strategy, then 
patients were randomized to angiography-guided or to FFR-guided group. 
FFR was measured in all the intermediate stenoses in both groups, but 
disclosed to the surgeons only if patients were allotted to the FFR-guided 
strategy. Patients in the angiography-guided group were operated following 
the initial angiogram-based strategy. Patients in the FFR-guided group were 
operated according to the hemodynamic stenosis significance by FFR. In this 
latter group, surgeons had to detail the intended procedure before and 
after disclosing the FFR values. 
 
Results: After randomization, 88 patients were included into the FFR-
guided group. Among them disclosure of FFR has changed bypass strategy 
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in 55%. Comparing to initial angiogram-based surgical strategy, disclosing 
FFR lead to significant reduction in necessity of on-pump surgery (81% vs 
69%, p=0.006; Figure 19A) and in total number of bypass grafts per patient 
(3[2;3] vs. 2[2;3], p=0.018) during the definitive surgical procedure. Of note, 
the number of procedures with >1 saphenous vein graft (SVG) was 
significantly reduced after FFR disclosure (43% vs. 31% after FFR disclosure, 
p=0.031; Figure 19B). Among the 64 vessels for which no revascularization 
was indicated based on the initial angiogram, 16 (25%) were finally 
bypassed based due to significant FFR. Among 108 lesions for which SVG 
implantation was indicated based on the initial angiogram, 25 (23%) were 
not bypassed after disclosing a preserved FFR value; while among 128 
lesions for which arterial graft was indicated, 15 (12%) were eventually not 
bypassed (Figure 19C).  At 1-year follow-up, outcomes were similar 
between patients with at least 1 change in strategy according to FFR and 
patient without any change in therapeutic decision. 
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Figure 19: A) Changes in bypass strategy (on-pump vs. off-pump) after FFR values disclosure; 
B) Changes in number of SVGs implantation (>1 SVG vs. ≤1 SVG) after FFR values disclosure; 
C) Changes in number of SVGs and arterial grafts after the disclosure of preserved FFR 
values. FFR indicates fractional flow reserve; SVGs indicates saphenous vein grafts.  
 
Conclusions: Change of procedural strategies after FFR assessment occurs 
in more than half of the cases, significantly simplifying the surgical protocol 
and without any untoward hazard on 1-year clinical outcome. 
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Chapter 15 
Fractional Flow Reserve-Guided Revascularization in 
Patients With Aortic Stenosis 
 
Background: FFR-guided revascularization strategies have been shown 
beneficial in patients with intermediate stenoses and multivessel CAD. The 
reliability and clinical usefulness of FFR has not been tested in patients with 
concomitant aortic stenosis (AS). Nevertheless, these are the very patients 
difficult to investigate with noninvasive functional testing and presenting 
with associated CAD in up to 50% of the cases.  
Aim: We aimed to investigate the impact of FFR measured at the time of 
the diagnostic coronary angiography on percutaneous and surgical 
revascularization strategies and its related clinical outcome in patients with 
AS. 
Methods: From 2002 to 2010, we retrospectively identified 106 patients 
with AS and significant CAD in which at least 1 intermediate lesion was 
either revascularized with an FFR value ≤ 0.80 or deferred with FFR > 0.8 
(FFR-guided group). Then, from 694 contemporary patients in which the 
decision to revascularize was based on angiography only, we matched 212 
as comparator (Angio-guided group). 
Inclusion criteria were: presence of at least 1 intermediate stenosis 
(diameter stenosis: 50-70%) of a major coronary artery at the time of 
angiography; aortic valve area ≤ 1.5 cm2 and/or aortic mean pressure 
gradient ≥ 20 mmHg. Severe AS was defined with a valve area ≤ 1 cm2 
58 
 
and/or aortic mean pressure gradient ≥ 40 mmHg. All patients underwent 
left/right sided heart catheterization. Aortic valve area was calculated with 
the Gorlin formula. PCI and surgical interventions were left to the 
operator’s discretion. CABG and aortic valve replacement (AVR) performed 
within 6 months from the diagnostic coronary angiography were referred to 
the index procedure. 
Primary end point was the rate of major adverse cardiac events (MACE), 
defined as overall death, MI, and repeat revascularization up to 5 years. 
Secondary end points were all the individual end points included in MACE 
and AVR. Follow-up was obtained through telephone contacts or outpatient 
visits. Date of death was retrieved from Belgium national death registry. 
Informed consent to the use of personal data was obtained from each 
patient. 
Results: The 2 groups were well matched with respect to clinical 
characteristics and AS severity did not differ between the groups. More 
patients in the FFR-guided group underwent PCI, while there was a trend 
towards more CABG in the Angio-guided group. Patients treated with PCI 
had lower AS severity as compared with patients treated with CABG (aortic 
valve area: 0.95 ± 0.29 vs. 0.76 ± 0.28, p <0.01; aortic mean gradient: 27 ± 
15 vs. 41 ± 20; p < 0.01). At baseline angiogram, number of diseased vessels 
was similar in the 2 groups. After functional assessment with FFR, the 
number of diseased vessels was significantly downgraded within the FFR-
guided group (p<0.01) and when compared to the Angio-guided group 
(p<0.01). In patients undergoing CABG, number of arterial grafts and 
anastomoses per patient was similar between the 2 groups, while 
significantly less venous conduits were used in the FFR-guided group, along 
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with less venous anastomoses. A trend towards less AVR was observed in 
the FFR-guided group. Clinical follow-up was available for all patients at a 
median time of 56 months. We found no difference in MACE up to 5 years, 
overall death, repeat revascularization and nonfatal MI between the 2 
groups. Similar results were found in the subgroup of patients with severe 
AS. When stratified by initial treatment strategy, MACE rate was still not 
significantly different among FFR- and Angio-guided groups. Combined 
CABG and AVR was associated with the best clinical outcome and Medical 
Therapy with the worst, while intermediate outcomes were reported in 
patients initially treated with PCI or AVR only (Figure 20). AVR at follow-up 
was performed in 9% of patients in the FFR-guided group (time to AVR: 31 
[22-43] months) vs. 6% in the Angio-guided group (time to AVR: 21 [7-54] 
months) (p= 0.28). At the latest follow-up available, cumulative AVR rate 
was still lower in the FFR-guided group (59 [55%] vs. 135 [63%]; p=0.16). 
 
Figure 20: Kaplan-Meier curves for survival free from events in the FFR-guided and Angio-
guided groups up to 5 years of follow-up: Survival free from MACE (upper left; p=0.98); 
Overall survival (upper right; p=0.68); Survival free from MI (lower left; p=0.83); Survival free 
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from revascularization (lower right; p=0.76). MACE, major adverse cardiac events; MI, 
myocardial infarction. 
 
Conclusions: FFR guidance impacts the management of selected patients 
with moderate or severe AS and coronary artery disease by resulting into 
deferral of aortic valve replacement, more patients treated with PCI, and in 
patients treated with CABG, into less venous grafts and anastomoses 
without increasing adverse event rates up to 5 years. 
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Chapter 16 
Clinical Outcome of Patients with Aortic Stenosis and 
Coronary Artery Disease Not Treated According to Current 
Recommendations 
 
Background: Degenerative AS is the most common valvular heart disease in 
the developed countries and is associated with significant CAD in up to 50 % 
of the cases. When both conditions are present and symptoms occur, 
current guidelines recommend surgical treatment with combined AVR and 
CABG. Yet, due to frequent comorbidities in these patients, treatment 
might diverge from guideline recommendations. 
Aim: In our study, we evaluated the real-world adoption of guideline 
recommendations in patients with combined moderate or severe aortic 
stenosis and significant coronary artery disease and assessed the impact of 
incomplete treatment strategies (i.e., diverging from classic AVR plus CABG) 
on the long-term clinical outcome. 
Methods and results: From 2002 to 2010, we assessed death up to 5 years 
in 650 patients with moderate/severe aortic stenosis and at least one 
coronary lesion (>50 %): 23% weretreated conservatively (medical therapy, 
MT), 17% with percutaneous coronary intervention (PCI), 11% with AVR, 
and 49% with combined CABG and AVR. Number of vessels treated per 
patient was higher in the combined CABG and AVR group as compared to 
the PCI-only group. In the latter, drug-eluting stents (DES) were used in 29 
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% of the cases. Surgical pump and clamp time was significantly longer in the 
combined CABG and AVR than in the AVR-only group.  
Clinical follow-up was available for all patients at a median time of 58 (21–
60)months. Figure 21 shows the survival curves for the four treatment 
groups.  
 
Figure 21: Overall survival in the four groups (log-rank 106.006; p<0.01). CABG: coronary 
artery bypass graft; AVR: aortic valve replacement; PCI: percutaneous coronary intervention. 
 
The adjusted Cox regression analysis confirmed the beneficial effect in 
terms of mortality of the CABG and AVR, AVR-only, and PCI-only group as 
compared to MT group (p <0.01). Other factors significantly associated with 
overall death were logistic EuroSCORE, atrial fibrillation, hyperlipidemia, 
and peripheral vascular disease. Direct comparison between PCI-only and 
AVR-only groups showed a trend toward better survival in the AVR-only 
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group (HR [95 % CI] 1.37 [0.85–2.2], p=0.19). As to the secondary endpoints, 
both AVR and revascularization at follow-up were significantly more 
frequent in the PCI group, followed by MT, with few or no events in the 
surgical groups. The time to AVR at follow-up was longer in the MT as 
compared to the PCI group (22 [19–37] vs. 11 [7–29]months, p=0.02). 
Kaplan-Meier curves showed improved survival in the MT group when AVR 
at follow-up was performed (p < 0.01), while a strong trend was observed in 
the PCI group (p=0.054) (Figure 22). At the adjusted Cox regression analysis 
corrected for confounders, AVR at follow-up confirmed its protective value 
in the MT group (HR [95 % CI] 0.39 [0.16–0.96], p=0.04), but not in the PCI 
group (HR [95 % CI] 0.65 [0.27–1.55], p=0.33). When patients with AVR at 
follow-up were excluded from the analysis, survival was still significantly 
higher in the PCI group (p <0.01) as compared with the MT group (Figure 
23), even after adjusting for confounders in the Cox regression analysis (HR 
[95 % CI] 0.62 [0.41–0.94], p=0.024). 
 
Figure 22: Impact of AVR performed at the follow-up on overall survival in the medical 
therapy (MT) group (log-rank 9.222; p < 0.01; on the left) and in the PCI group (log-rank 
3.725; p=0.054; on the right).  
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Figure 23: Overall survival in the medical therapy and PCI-alone groups after excluding 
patients undergoing AVR at the follow-up (log-rank 11.324; p<0.01).  
 
Conclusions: In this real-world experience, only half of the symptomatic 
patients with moderate or severe AS and CAD initially underwent combined 
CABG and AVR as recommended by the guidelines. Our results confirm that 
this treatment strategy is associated with the best outcome at 5 years. 
Nevertheless, in patients in whom combined CABG and AVR was not 
performed, either PCI or AVR significantly improve survival at 5 years as 
compared to medical therapy. These findings might have important clinical 
implications especially in frail patients excluded even from TAVR but who 
might benefit from a percutaneous revascularization strategy. 
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Chapter 17 
Impact of Right Atrial Pressure on Fractional Flow Reserve 
Measurements: Comparison of Fractional Flow Reserve 
and Myocardial Fractional Flow Reserve in 1,600 Coronary 
Stenoses 
 
Background: FFR is defined as the ratio of maximal blood flow in the 
stenotic coronary artery to the maximal blood flow if the same artery were 
normal. Accordingly, FFR expresses to what extent a given stenosis limits 
the maximal achievable myocardial flow, and, as a corollary, to what extent 
myocardial flow can be improved by revascularization of the epicardial 
segment. This ratio of 2 flows can be derived from the ratio of their 
respective driving pressures during maximal hyperemia. In fact, the concept 
of FFR enables the assessment of the separate contribution of maximum 
coronary and collateral blood flow to myocardial blood flow, all expressed 
as a ratio to their normal values. The latter is called then myocardial FFR 
(FFRmyo), and for its calculation theoretically right atrial pressure should be 
included. Because in the majority of patients with coronary artery disease 
right atrial pressure is low, the latter is neglected in the calculation of FFR. 
Yet whether FFR measurement is still reliable across a wide range of 
hemodynamic conditions, such as in patients with heart failure, is not clear. 
Aim: This study sought to assess the impact of a wide range of mean right 
atrial pressure (Pra) on FFR measurements. 
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Methods and results: In 1,676 stenoses of 1,235 patients undergoing left-
right heart catheterization for ischemic (642 [52%]) or valvular heart 
disease (593 [48%]), we compared the FFR values calculated without 
accounting for Pra (FFR=Pd/Pa) to the corresponding myocardial fractional 
flow reserve (FFRmyo) values accounting for Pra (FFRmyo= Pd - Pra/Pa - Pra). The 
FFR and FFRmyo were measured and calculated for every coronary stenosis 
in the range between 30% and 90% diameter stenosis by visual estimate. 
The average FFR value was 0.85 (interquartile range [IQR]: 0.78 to 0.91), 
and the average FFRmyo was 0.83 (IQR: 0.76 to 0.90). Correlation and 
agreement between the 2 parameters were excellent (r2= 0.987; slope 
1.096±0.003). The median difference between FFR and FFRmyo was 0.01 
(IQR: 0.01 to 0.02) (Figure 24). In patients, with normal right atrial pressure 
(Pra≤5 mmHg), the median difference between FFR and FFRmyo was minimal: 
0.01 (IQR: 0.00 to 0.01). When grouping the patients into tertiles of Pra, a 
statistically significant increase was observed in the difference between FFR 
and FFRmyo over the 3 groups: 0.01 (IQR: 0.00 to 0.01) versus 0.01 (IQR: 0.01 
to 0.02) versus 0.02 (IQR: 0.01 to 0.03), respectively; p<0.001 (Figure 25). 
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Figure 24: (A) The correlation and agreement between fractional flow reserve (FFR) and 
myocardial fractional flow reserve (FFRmyo) in the overall population. Note that there is 
minimal deviation between FFR and FFRmyo at the lower third of the entire range of FFR 0 to 
1. (B) Despite the deviation between FFR and FFRmyo, the vast majority of the measurements 
have clinical agreement (green areas), a minor portion of FFR above 0.80 yields an FFRmyo 
≤0.80 (orange area), and no FFR above 0.80 yields an FFRmyo ≤0.75 (pink area). 
 
 
Figure 25: A significant constant increase was observed in the difference between fractional 
flow reserve (FFR) and myocardial fractional flow reserve (FFRmyo) over the tertiles by right 
atrial pressure. However, even in the highest tertile the mean difference remained clinically 
minimal. 
 
 The median difference between FFR and FFRmyo in lesions with FFR above 
0.80 was 0.01 (IQR: 0.00 to 0.01). Out of 1,146 stenoses with an FFR >0.80, 
none had an FFRmyo ≤0.75, and 110 (9%) stenoses had an FFRmyo ≤0.80. In 
the latter group, the difference between FFR and FFRmyo was 0.02 (IQR: 0.02 
to 0.03), yet with a Pra statistically significantly higher than in the overall 
population (9 mm Hg [IQR: 7 to 12 mm Hg]; p < 0.001). Receiver operator 
characteristic analysis showed that an 0.80 FFR value has 83% sensitivity 
and 100% specificity in predicting an FFRmyo ≤0.80. Diagnostic accuracy 
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expressed as area under the curve was 0.913 (95% confidence interval: 
0.896 to 0.931). The best cutoff value of FFR for predicting an FFRmyo ≤0.80 
was found to be 0.82, with 96% sensitivity and 97% specificity. These 
findings remained unchanged when accounting for multiple lesions for 
some patients or when selecting at most 1 lesion per patient in a random 
fashion, justifying the negligible impact of any clustering effect. 
We assessed 2 models of possible impact of Pra on FFR measurements 
based on the available data set. In the first model, FFRmyo was calculated for 
the same patient population by applying 3 fixed values of potential Pra: 5 
mmHg, 10 mmHg, and 20 mmHg. A statistically significant increase was 
observed in the difference between FFR and FFRmyo over the 3 values, but it 
remained remarkably low (0.01 [IQR: 0.01 to 0.01] vs. 0.02 [IQR: 0.01 to 
0.03] vs. 0.04 [IQR: 0.03 to 0.07], respectively; p < 0.001). In the 5 and 10 
mmHg groups, values of FFR >0.80 never yielded an FFRmyo ≤0.75; whereas 
in the 20 mmHg group, this occurred in 4% of the cases. In addition, no FFR 
values >0.82, >0.83, or >0.87 would have yielded an FFRmyo ≤0.80 in the 3 
groups, respectively (Figure 26). In the second model, we investigated in 
the same population what Pra value could have a relevant impact on the 
following threshold values of FFR: 1) FFR >0.80 and FFRmyo ≤0.80; or 2) FFR 
>0.80 and FFRmyo ≤0.75. With a normal Pra, FFR >0.80 never yields an FFRmyo 
≤0.80 with FFR >0.82. With normal Pra (≤5 mm Hg), FFR >0.80 never yields 
an FFRmyo ≤0.75. The latter might only occur when the FFR is close to the 
cutoff value of 0.80 or Pra is particularly (even nonphysiological) high.  
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Figure 26: (A) Fractional flow reserve (FFR) and related myocardial fractional flow reserve 
(FFRmyo) values, calculated by applying 3 different potential Pra values: 5, 10, and 20 mm Hg. 
A statistically significant increase was observed in the deviance from agreement between 
FFR and FFRmyo over the 3 groups. (B) No FFR values >0.82, >0.83, or >0.87 would have 
yielded an FFRmyo ≤0.80 in the 5, 10, or 20 mm Hg groups, respectively. 
 
Conclusions: The difference between FFR and FFRmyo was minimal even in 
patients with markedly increased Pra. FFR values above the gray zone (i.e., 
>0.80) did not yield values below the gray zone (i.e., ≤0.75) in any case, 
which suggests that the impact of right atrial pressure on FFR measurement 
is indeed negligible. 
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Chapter 18 
Fractional flow reserve in patients with non-valvular left 
ventricular dysfunction 
 
Background: In patients with LVD and CAD the indication for 
revascularization is controversial. FFR has been associated with improved 
clinical outcomes in patients with preserved left ventricular systolic 
function. Moreover, the use of FFR has been recently proven to be reliable 
in the presence of elevated right filling pressures in our single center 
experience. Nevertheless, its impact in patients with reduced ejection 
fraction has never been investigated. 
Aim: to evaluated the impact of FFR on: a) reclassification of stenosis 
significance; b) indication to revascularization; c) revascularization strategy; 
d) long-term clinical follow-up. 
Methods: From 2002 to 2010, we retrospectively identified 433 patients 
with non-valvular LVD and significant CAD in which at least 1 intermediate 
lesion was either revascularized with an FFR value ≤ 0.80 or deferred with 
FFR > 0.8 (FFR-guided group). Then, from 2399 contemporary patients in 
which the decision to revascularize was based on angiography only, we 
matched 866 as comparator (Angio-guided group). Inclusion criteria were: 
presence of at least 1 intermediate stenosis (diameter stenosis: 50-70%) of 
a major coronary artery at the time of angiography; left ventricular ejection 
fraction (LVEF) ≤ 50%. Exclusion criteria were: presence of cardiogenic 
shock at the time of the index procedure; moderate or severe valvular heart 
disease requiring surgical repair or replacement. The primary endpoint of 
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this study was the rate of major adverse cardiovascular and cerebrovascular 
events (MACCE), defined as all-cause death, MI, revascularization and 
stroke at 1 and 5 years of follow-up. Secondary endpoints were all the 
individual end points included in the primary endpoint, HF hospitalization 
and unplanned cardiac admission. 
Results: After hemodynamic assessment, the number of stenotic vessels 
per patient was significantly downgraded within the FFR-guided group 
(from 2.0 ± 0.84 to 1.4 ± 0.98; p<0.01) and compared with the Angio-guided 
group (1.4 ± 0.98 vs. 2.02 ± 0.84; p<0.01). This was associated with a 
significantly lower revascularization rate as compared with the Angio-
guided group (52% vs. 61%; p <0.01). PCI was performed more frequently in 
the FFR-guided group (36% vs. 28% in the angio-guided group; p<0.01); 
while CABG was more often the therapy of choice in the angio-guided 
group (32% vs. 16% in the FFR-guided group, p<0.01) (Figure 27).  
 
Figure 27: Difference in treatment strategies between the FFR- and the Angio-guided group. 
Revasc indicates revascularization. CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention; MT, medical therapy. 
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In patients undergoing CABG, there was significantly more off-pump (37% 
vs. 11%; p< 0.01); minimally invasive surgery (7% vs. 1%; p<0.01); lower rate 
of venous grafts per patient (1.02 ± 0.8 vs. 1.28 ± 0.7; p=0.01) in the FFR-
guided group. At 1-year follow-up, we observed a significant lower rate of 
MACCE, all-cause death and stroke in the FFR-guided group (Figure 28). The 
difference in MACCE and mortality was confirmed up to 5 years. In both 
groups patients treated surgically had the worst outcome, with the majority 
of events occurring early after the index procedure. In patients treated 
medically, we observed lower MACCE and mortality rates in the FFR-guided 
group (Figure 29). 
 
Figure 28: Kaplan–Meier curves reporting the cumulative incidence of major adverse 
cardiovascular and cerebrovascular events (MACCE) (A) and all cause Death (C); landmark 
analysis before and after 1-year timepoint for MACCE (B) and all cause Death (D). 
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Figure 29: Kaplan–Meier curves reporting the cumulative incidence of major adverse 
cardiovascular and cerebrovascular events (MACCE) in patients treated with coronary artery 
bypass grafting (CABG) (A), Percutaneous coronary intervention (PCI) (B) or medical therapy 
(C). 
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Conclusions: In patients with non-valvular LVD and CAD, an FFR-guided 
revascularization strategy is associated with a lower rate of CABG and a 
higher rate of PCI and medical therapy. At 5-year follow-up, FFR was 
associated with lower MACCE and mortality rate and safer deferral of 
patients towards medical therapy as compared with an angio-guided 
strategy. 
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Part IV 
 
Angiography-derived FFR technologies 
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Chapter 19 
Diagnostic Accuracy of Fast Computational Approaches to 
Derive Fractional Flow Reserve From Diagnostic Coronary 
Angiography: The International Multicenter FAVOR Pilot 
Study 
 
Background: numerous studies have documented favorable clinical 
outcomes for FFR-guided coronary interventions in patients with stable 
CAD. Despite the clear advantages and the Class I recommendations by the 
European Society of Cardiology Guidelines, the clinical adoption of FFR has 
been variable and slow. A tool that allows calculating FFR without the use of 
costly pressure wires and the administration of adenosine could increase 
the adoption of FFR.  
Aim: we performed a prospective multicenter study to compare the 
diagnostic performance of these QFR computational models as compared 
with pressure wire-derived FFR. 
Methods: The prospective, observational, multicenter FAVOR (Functional 
Assessment by Various Flow Reconstructions) pilot study investigated 
offline computation of QFR as compared with conventional pressure wire-
based FFR as the standard reference. Exclusion criteria were 
contraindications to adenosine or adenosine triphosphate administration. 
Angiographic inclusion criteria were: 1) ≥ 1 lesion with 30% to 80% diameter 
stenosis by VE; and 2) FFR measurement deemed feasible by the operator. 
Exclusion criteria were: 1) ostial left main (LM) or ostial RCA lesion; and 2) 
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prior CABG of the interrogated vessels. The QFR computation was based on 
the underlying principles: 1) coronary pressure remains constant through 
normal epicardial coronary arteries; 2) the amount of pressure drop is 
determined by the stenosis geometry and the flow moving through the 
stenosis, described by the fluid dynamic equations; 3) the stenosis 
geometry can be characterized by the deviation of the diseased lumen 
sizing with respect to the reference sizing, i.e., the healthy lumen as if there 
was no stenosis, by 3D QCA; and 4) Coronary flow velocity is preserved 
distally relative to proximal flow velocity, and the mass flow rate in the 
main coronary arteries decreases with the tapering of the arteries due to 
the presence of side branches. Hence, the mass flow rate at each location 
along the interrogated vessel can be determined by the mean flow velocity 
and the reference sizing from 3D QCA. 
The following 3 QFR computations were performed, based on the different 
mean hyperemic flow velocities:  
1. The fQFR pullback: a fixed empiric HFV of 0.35 m/s that was 
derived from previous FFR studies was used for computation, and then a 
comparison with the pressure wire-based FFR was performed. 
2. The cQFR pullback: frame count analysis was performed 
separately on the 2 diagnostic angiographic projections without 
pharmacologically induced hyperemia, and the modelled HFVs were 
derived by which the software computed 2 new QFR pullbacks. The analyst 
chose the QFR pullback based on best image quality (most well-defined 
contrast-flow) in the frame count analysis as the cQFR pullback to compare 
with the pressure wire-based FFR. 
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The computational FFR, denoted as quantitative flow ratio (QFR), can be 
obtained using 3 different flow models: 1) a fixed empiric hyperemic flow 
velocity (HFV), derived from previous FFR studies (fixed-flow QFR [fQFR]); 2) 
modelled HFV derived from coronary angiography without 
pharmacologically induced hyperemia (contrast-flow QFR [cQFR]), that is, 
the contrast flow was converted into the virtual hyperemic flow based on 
data derived from previous studies, and cQFR was computed as if 
adenosine was actually used; and 3) measured HFV derived from coronary 
angiography during adenosine-induced maximum hyperemia (adenosine-
flow QFR [aQFR]).  
3. The aQFR pullback: frame count analysis was performed 
separately on the 2 angiographic projections that were acquired during 
hyperemia, induced by intravenous administration of adenosine or 
adenosine triphosphate. The “real” HFVs were derived and the software 
calculated 2 new QFR pullbacks. The analyst chose the QFR pullback based 
on best image quality in the frame count analysis as the aQFR pullback to 
compare with the pressure wire-based FFR. 
The QFR value at the position that matched the location of the pressure 
transducer on the pressure wire was used for comparison with the FFR 
value measured by the pressure wire. Representative examples of 
computation of QFR using different flow models are shown in Figure 30. 
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Figure 30: (A, B) Coronary angiography shows RCA with serial stenoses. The FFR measured by 
pressure wire at * was 0.74. (C) The computed fixed-flow QFR at * was 0.75. (D) The 
computed contrast-flow QFR was 0.76, and the mean flow velocity calculated on 
angiographic runs acquired without maximum hyperemia was 0.17 m/s. The modelled 
hyperemic flow velocity was 0.34 m/s. (E) The computed adenosine-flow QFR at * was 0.75, 
and the hyperemic flow velocity calculated on angiographic runs acquired during maximum 
hyperemia was 0.37 m/s. FFR= fractional flow reserve; aQFR= adenosine-flow QFR; cQFR= 
contrast-flow QFR; fQFR= fixed-flow QFR; QFR= quantitative flow ratio; RCA= right coronary 
artery. 
 
Results: The QFR and FFR from 84 vessels in 73 patients with intermediate 
coronary lesions were compared. Mean angiographic DS% was 46.1 ± 8.9%; 
27 vessels (32%) had FFR ≤ 0.80. Good agreement with FFR was observed 
for fQFR, cQFR, and aQFR, with mean differences of 0.003 ± 0.068 (p= 0.66), 
0.001 ± 0.059 (p= 0.90), and -0.001 ± 0.065 (p= 0.90), respectively. The 
overall diagnostic accuracy for identifying an FFR of ≤0.80 was 80% (95% 
confidence interval [CI]: 71% to 89%), 86% (95% CI: 78% to 93%), and 87% 
(95% CI: 80% to 94%). The area under the receiver-operating characteristic 
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curve was higher for cQFR than fQFR (difference: 0.04; 95% CI: 0.01 to 0.08; 
p< 0.01), but did not differ significantly between cQFR and aQFR 
(difference: 0.01; 95% CI: -0.04 to 0.06; p= 0.65). Compared with DS%, both 
cQFR and aQFR increased the area under the receiver-operating 
characteristic curve by 0.20 (p < 0.01) and 0.19 (p < 0.01) (Figure 31). The 
positive likelihood ratio was 4.8, 8.4, and 8.9 for fQFR, cQFR, and aQFR, 
with negative likelihood ratio of 0.4, 0.3, and 0.2, respectively. 
 
Figure 31: (A) Per patient. (B) Per vessel. The AUC was significantly higher for fQFR, cQFR, 
and aQFR, as compared with the anatomic parameter DS%. AUC= areas under the receiver-
operator characteristics curve; DS%= percent diameter stenosis. Other abbreviations as in 
29. 
 
Conclusions: QFR computation improved the diagnostic accuracy of 3-
dimensional quantitative coronary angiography-based identification of 
stenosis significance. The favorable results of cQFR that does not require 
pharmacologic hyperemia induction bears the potential of a wider adoption 
of FFR-based lesion assessment through a reduction in procedure time, risk, 
and costs. 
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Chapter 20 
FFRangio: theoretical basis 
 
FFRangio is a new angiography-derived FFR technology (developed by 
CathWorks, Ltd) which provides a 3-dimensional (3D) functional 
angiography mapping of the coronary tree with superimposed, color-coded, 
FFR values. Stated another way, FFRangio displays a functional angiogram. 
This computational method is based on a rapid flow analysis after a 
classification of the dynamic characteristics of the vessels in conjunction 
with the patient’s hemodynamic information, allowing to assess FFR using 
routine angiograms within a few minutes of automatic processing.  
The primary element of FFRangio is the proprietary 3D rebuild of the coronary 
tree from 2-dimensional (2D) images. This is accomplished automatically by 
reconstructing the geometry of the tree, including its centerlines and cross-
sections at each point along them, as well as the exact topology. The 
reconstruction is based on the known geometry of ≥3 projections from 
single-plane angiograms and uses epipolar ray tracing (Figure 32A) together 
with mathematical constraints enforcing the tree’s structure. The system is 
able to construct each vessel separately such that each region/ 
branch/lesion is not necessarily reconstructed from the same views, yet at 
the same time the tree topology is preserved and adheres to that reflected 
in all of the 2D images. A self-validation step follows whereby the 3D shape 
of the coronary arteries is projected back onto the 2D images used in its 
recovery, allowing for this verification loop to be inspected by the user. 
Finally, the 3D engine contains a compensation mechanism, whereby it uses 
all available projections at once to compensate for the different x/y/z 
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displacements apparent in the breathing and patient movements. In 
addition, panning of the table and C-arm is not recommended during the 
cine acquisition. Main vessels and side vessels (up to the first or second 
generation) must preserve the correct connectivity, stemming from the 2D 
projections (Figures 32B and 32C). Segment-node representation is 
maintained, whereas uneven motion displacements are compensated for 
using iterated-closest-point alignment. The coronary tree, represented by 
position and diameter values for all vessels, can then be surfaced using a 
triangular mesh and rendered to display a 3D coronary model (Figure 32D).  
 
Figure 32: A)  epipolar ray tracing; B) connectivity stemming from the 2D projections; C) 3D 
coronary model; D) triangular mesh.  
 
Next, the system scans the entire reconstructed tree in 3D and analyzes 
each branch and each bifurcation (or trifurcation), looking for narrowed 
regions. Diameter stenosis is clinically defined as the proportion between 
the actual diameter of the measured vessel versus that of the healthy 
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vessel. An automatic stenosis analyzer, therefore, requires 3 components 
critical to the proper evaluation of the extent of the lesion. Because 
stenoses vary in length, location, and spread, it is necessary to look at each 
vessel at different scales. The first is at the segment level, where a segment 
is defined as the portion of a vessel that connects 2 junctions. The second 
scale is the branch level, looking at the entire vessel as a whole. Finally, as a 
third scale, the junction level is where a parent branch bifurcates (or 
trifurcates) into secondary or tertiary branches. At each level, a tailored 
process starts with an accurate detection of vessel walls, followed by 
determination of the reference diameter. It then evaluates the magnitude 
of flow resistance because each narrowing is added to the tree. A 
hemodynamic evaluation follows, where the contribution of each 
narrowing to the total resistance to flow is taken into account, and a 
subsequent lumped model is built. The contribution to the control of flow 
of certain vessels depends on their impact on overall resistance. The 
resistance of a vessel can be readily estimated from its length and diameter, 
applying Poiseuille law, and neglecting entrance effects and peculiarities of 
rheology. Applying various models to infer resistance, based on Poiseuille 
forces, Bernoulli forces, and the resistance model described in the study by 
Kirkeeide, all yield equivalent accuracies of the FFRangio values. 
The extent of the model is such that it includes a stenosis and spreads 
distally as far as the resolution of the imaging modality allows. The number 
of bifurcations is limited by the resolution to which vascular width can be 
determined from the images (>0.5 mm), and the availability of a larger 
number of measurable bifurcations is a potential advantage for a more 
complete reconstruction of the detailed vascular resistance. The 
accumulated volume of the coronary vessels and total coronary length, 
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calculated from a reconstruction of its geometry, enables an estimation of 
normal supply derived from the microcirculatory bed resistance. 
The solution of the lumped model based on the inlet and outlet boundary 
conditions allows to evaluate ratios of flow rate for stenosed versus healthy 
coronary trees. A color-mapped mesh is then generated and displays the 
FFR values at every location, as long as thevessel diameter is not limited by 
image resolution. 
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Chapter 21 
Fractional Flow Reserve Derived From Routine Coronary 
Angiograms 
 
Background: Pressure wire-based FFR has become the standard of 
reference for decision making regarding coronary revascularization. 
Deriving FFR from routine angiograms could facilitate the uptake of FFR-
based clinical decisions. Several angiography-derived FFR methods have 
recently been introduced. These methods are based on computational fluid 
dynamic simulations. FFRangio is a novel technology providing a functional 
angiography mapping of the coronaries in 3D based on a rapid flow analysis 
of a dynamically derived lumped model that can assess FFR using routine 
angiograms and hemodynamic data. 
Aim: to evaluate in an off-line analysis the diagnostic accuracy of FFRangio 
compared with invasive FFR.  
Methods: theoretical aspects of the FFRangio have been extensively 
described in chapter 20. Eighty-eight patients with stable angina were 
included in this first in man study. FFR measurements were performed for 
clinical reasons in ≥ 1 coronary artery. Patients with left main stenoses, 
ostial stenosis, in-stent restenosis at the target vessel, and previous bypass 
surgery were excluded (7.7%). At least 2 angiographic projections of the 
vessel to be measured were acquired at 15 frames/s. The exact inclination 
of the radiographic tube was left to the operator’s discretion. Care was 
taken to fill the artery as completely as possible with contrast medium and 
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to image the entire coronary tree at each view. The FFRangio computations 
were performed offline from Digital Imaging and Communications in 
Medicine (DICOM) format files by operators not present in the 
catheterization laboratory and blinded to the invasive FFR results. Each 
series of DICOM cine sequences was loaded and processed along with the 
patient’s mean aortic pressure obtained at the time the angiogram was 
acquired. Invasive FFR measurements were performed in duplicate with 6-F 
GCs, a pressure monitoring wire, and intracoronary adenosine (100– 200 
µg). Care was taken to document the exact anatomical position of the 
sensor. To test interobserver variability and the possible influence of 
human factors on the results of FFRangio, 2 independent operators analyzed 
all angiograms. 
Results: A total of 101 lesions were analyzed, 30% of which had FFR values 
between 0.70 and 0.90. FFRangio was calculated and compared to invasive 
FFR measurements at the exact location of the sensor (Figure 33A). A high 
degree of concordance was found between 2 measurements of FFRangio 
performed by 2 different operators (interclass correlation coefficient of 
0.97; p < 0.001). Figure 33B shows linear regression analyses for the 2 
independent observers. We found that invasive FFR was a robust predictor 
of FFRangio, with 86.8% of the variability of FFRangio explained by the invasive 
FFR values; the β coefficient of invasive FFR was 0.855 (95% confidence 
interval [CI]: 0.789 to 0.922) and the intercept was 0.124 (95% CI: 0.068 to 
0.179). The estimated bias was 0.004 ± 0.042 and did not differ significantly 
from zero. The 95% limits of agreement were -0.1 to 0.1. We used 0.8 as 
the cutoff value for FFRangio, and found that the sensitivity, specificity, and 
diagnostic accuracy were 88%, 98%, and 94%, respectively. 
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Figure 33: A case demonstrating a significant lesion in the left coronary tree (A). Correlation 
between invasive FFR and FFRangio is represented by 2 different operators (B). FFR= fractional 
flow reserve; FFRangio= angiography-derived FFR. 
 
Conclusions: This first-in-human study indicated high reproducibility and 
diagnostic accuracy of FFRangio compared with invasive FFR. The data were 
obtained in patients with characteristics encountered in most PCI trials and 
included relatively well-delineated lesions associated with a large range of 
FFR values. If the short turnaround time needed to obtain the FFRangio value 
and the diagnostic accuracy are confirmed in larger studies, FFRangio may 
foster a wider adoption of FFR-based decision making for revascularization 
in patients with CAD. 
Chapter 22 
Validation Study of Image-Based Fractional Flow Reserve 
During Coronary Angiography 
88 
 
 
Background: FFR is the gold standard for hemodynamic assessment of 
coronary intermediate stenoses but remains underused because of its 
invasive nature. Several image-based FFR methodologies exist that are 
based on computational fluid dynamics simulation. FFRangio uses routine 
angiograms to generate a complete 3-dimensional coronary tree with color-
coded FFR values at any epicardial location, without the need of a pressure 
wire or hyperemic stimulus or the need of computational fluid dynamics 
(CFD) simulation. 
Aim: to assess the diagnostic performance and interobserver 
reproducibility of FFRangio in patients with stable coronary artery disease. 
Methods: theoretical aspects of the FFRangio was described in chapter 20. 
Coronary angiography and invasive FFR measurements protocols as well as  
the offline FFRangio computation were illustrated in chapter 21. To test 
interobserver variability, and the possible influence of human factors on the 
results of FFRangio, 2 independent operators analyzed all angiograms. The 
mean values were compared with the FFR measurements obtained with the 
invasive pressure wire, at the exact location of the sensor.  
Results: A total of 199 patients were enrolled for the study, but analysis 
was performed only in 184 of them (123 men, 203 stenoses) because of 
protocol violation in 8 cases (eg, post coronary bypass surgery, aorto-ostial 
stenosis, and in-stent restenosis lesions) and inadequate quality of the 
angiogram in 7 patients. Lesions were distributed as follows: 118 in the left 
anterior descending, 30 in the left circumflex, 39 in right coronary arteries, 
5 in intermediate branches, 2 in the diagonal branch, and 9 in the obtuse 
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marginal branch. Sixty-seven percent of the invasive FFR values were 
between 0.70 and 0.90, and 35% between 0.75 and 0.85. The average 
intraclass correlation coefficient for the 2 measurements of FFRangio 
conducted by 2 different operators blinded to each other and blinded to 
the results of invasive FFR was 0.962 with a 95% confidence interval from 
0.95 to 0.971 (P<0.001; Figure 34). Figure 35 shows the correlation between 
the mean FFRangio value as the dependent variable and the wire-based FFR 
as the predictor variable and the corresponding Bland–Altman plots. The 
estimated bias was 0.007, indicating that FFRangio values do not 
systematically underestimate or overestimate invasive FFR values. The 95% 
limits of agreement were −0.096 to 0.112. Visual estimation of the Bland-
Altman plot indicates that the differences between the 2 methods, and the 
scatter around the bias line, are stable as the average increases. 
 
Figure 34: Correlation (scatter plot) of the FFRangio values obtained by 2 blinded operators 
(left), with the corresponding Bland–Altman plot (right). The intraclass correlation 
(consistency of agreement) was found to be 0.962 (95% confidence interval, 0.950–0.971).  
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Figure 35: Correlation between invasive fractional flow reserve (FFR) and FFRangio (left) and 
the corresponding Bland–Altman plot (right). FFRangio values are the mean of 2 independent 
analyses performed by different observers. Invasive FFR values are the mean of 2 
measurements done by the same operator. 
 
Using 0.8 as a cutoff value for FFRangio and invasive FFR, the sensitivity, 
specificity, diagnostic accuracy, positive likelihood ratio, and negative 
likelihood ratio for FFRangio were 88%, 95%, 93%, 22, and 0.12, respectively. 
Figure 36 shows the plots of invasive FFR values compared with FFRangio, 
diameter stenosis by visual estimate, and diameter stenosis by quantitative 
coronary angiography. The corresponding areas under the respective ROC 
curves are 0.97, 0.57, and 0.61.  
 
Figure 36: Plots of invasive fractional flow reserve (FFR) values compared with FFRangio, 
diameter stenosis by visual estimate, and diameter stenosis by quantitative coronary 
angiography. The red borders indicate the values misclassified by FFRangio, diameter stenosis 
by visual estimate, and diameter stenosis by quantitative coronary angiography, 
respectively. 
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Conclusions: The FFRangio shows a high concordance with invasive FFR and 
can be obtained within minutes in the setting of a regular coronary 
angiogram. If confirmed in a larger study, FFRangio appears as an easy means 
of integrating anatomy and physiology with high spatial resolution in the 
catheterization laboratory. This, in turn, may facilitate the adoption of FFR-
based clinical decision making regarding coronary revascularization. 
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Part V 
 
Platelet and microvascular function  
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Chapter 23 
Effects of Prasugrel Versus Clopidogrel on Coronary 
Microvascular Function in Patients Undergoing Elective 
PCI 
 
Background: Microvascular impairment has been reported in patients on 
clopidogrel undergoing elective PCI. The related potential mechanisms 
might include the high residual platelet reactivity (PR) observed in a 
substantial proportion of these patients pretreated with clopidogrel at the 
time of PCI. Alternatively, microvascular constriction could occur possibly as 
consequence of transient endothelial dysfunction related to impaired 
platelet response to clopidogrel.  
Aim: to evaluate whether prasugrel might exert a protective effect on 
microcirculation during elective PCI in patients with stable CAD scheduled 
for elective PCI. 
Methods: The prospective randomized double-blind controlled PROMICRO-
2 (PROtecting MICROcirculation during coronary angioplasty) trial enrolled 
thienopyridine-naive patients with stable CAD referred to elective PCI of an 
isolated, functionally significant (FFR <0.80) lesion located in the proximal 
twothirds of a major coronary artery. Patients were randomized to either 
prasugrel (60 mg) or clopidogrel (600 mg) at least 12 h before PCI. All 
patients received a 500-mg loading dose of aspirin the day before the 
procedure. CFR, IMR, and FFR were measured in each patient before and 
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after PCI. High-sensitivity troponin T (hs-TnT) was assessed in blood samples 
before, and 8 and 24 h after PCI.  
Results: At baseline, FFR, CFR, and IMR were similar in the 2 study groups. 
Patients in the prasugrel group showed significantly lower post-PCI IMR 
values compared with those in the clopidogrel group. Compared with 
baseline, IMR increased post-PCI in the clopidogrel group (p= 0.009), but 
not in the prasugrel group (p= 0.299). Repeated measures 2-way analysis of 
variance (ANOVA) showed a significant interaction between treatment (i.e., 
prasugrel vs. clopidogrel) and time in determining IMR values (p= 0.047). 
Consistently, post-PCI CFR was significantly higher in the prasugrel 
compared with the clopidogrel group. Compared with baseline, CFR 
remained unchanged post-PCI in the clopidogrel group (p= 0.563), whereas 
increased in the prasugrel group (p= 0.036). Repeated-measures 2-way 
ANOVA showed a nonsignificant interaction between treatment (i.e., 
prasugrel vs. clopidogrel) and time in determining CFR values (p= 0.053). 
Baseline Hs-TnT was 4.8 (IQR: 3.2 to 10.1) ng/ml in the prasugrel group 
versus 5.1 (IQR: 3.0 to 12.8) ng/ml in the clopidogrel group (p= 0.845). Post-
PCI Hs-TnT was 12.8 (IQR: 7.7 to 23.6) ng/ml in the prasugrel group versus 
25.6 (11.8 to 50.6) ng/ml in the clopidogrel group (p= 0.032). Repeated-
measures 2-way ANOVA showed a significant interaction between 
treatmentand time in determining log-transformed Hs-TnT values (p= 
0.044). Periprocedural Hs-TnT increase (i.e., difference between baseline 
and highest post-procedural values) was significantly lower in the prasugrel 
group compared with the clopidogrel group (6.6 [2.5 to 9.7] ng/ml vs. 15.8 
[5.9 to 38.0] ng/ml; p= 0.034). 
95 
 
Conclusions: the results of the PROMICRO-2 trial suggest that more 
intensive antiplatelet regimens might offer additional benefit compared 
with clopidogrel also in the setting of elective PCI. 
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Chapter 24 
Platelet Reactivity and Coronary Microvascular 
Impairment After Percutaneous Revascularization in 
Stable Patients Receiving Clopidogrel or Prasugrel 
 
Background: Currently recommended antiplatelet therapy for patients with 
stable CAD undergoing elective PCI is unable to provide effective platelet 
inhibition in all patients. Despite pretreatment with aspirin and clopidogrel, 
a large proportion of these patients show high residual PR at the time of 
PCI. Coronary vessel manipulation especially during complex PCI is an 
additional trigger for transient increase in PR. Prasugrel provides more 
potent platelet inhibition than clopidogrel, though it is unknown whether it 
might also prevent PCI-related platelet activation. 
Aim: In stable patients undergoing elective PCI, we compared: (1) the 
effects of prasugrel vs. clopidogrel on peri-procedural variations of PR; (2) 
the correlation of platelet inhibition potency with PCI-induced coronary 
microvascular impairment. 
Methods: forty thienopyridine-naive patients were randomly assigned to a 
loading dose of either prasugrel 60 mg (n=20) or clopidogrel 600 mg (n=20) 
at least 12 hours before PCI. At the time of PCI, we assessed adenosine 
diphosphate (ADP)-induced PR with the Multiplate Analyzer, and IMR in the 
treated coronary, both at baseline and post-procedure. 
Results: Patients in the prasugrel group showed significantly lower ADP-
induced PR both at baseline (16.0±8.7 vs. 33.9±18.0 AU, p<0.001) and post-
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PCI (16.2±9.0 vs. 39.0±18.6 AU, p<0.001) as compared with the clopidogrel 
group. While a significant peri-procedural increase in PR was observed in 
the clopidogrel group (p=0.008), PR was not significantly different before 
and after PCI in the prasugrel group (p=0.822) (Figure 37). Repeated 
measures 2-way ANOVA showed a significant interaction between 
treatment and time in determining PR values (p=0.022). Periprocedural 
variation (defined as the difference between after and before PCI) of PR 
(∆PR) was 5.1±7.6 AU in the clopidogrel group and 0.3±4.9 in the prasugrel 
group (p=0.014). 
 
Figure 37: Platelet reactivity. Adenosine diphosphate-induced platelet reactivity (PR) at 
baseline and post-PCI. Panel A: patients treated with clopidogrel. Panel B: patients treated 
with prasugrel. Data shown as mean and standard deviation. 
 
A significant correlation was observed between baseline and post-PCI IMR, 
both in the overall population (r=0.689, p<0.0001) and in the two study 
groups separately (clopidogrel: r=0.623, p=0.003; prasugrel: r=0.751, 
p<0.0001). The change between baseline and post-PCI IMR was not 
significantly different between the two study groups, neither when 
considering the net numerical difference (6±9 in the clopidogrel group vs. 
2±7 in the prasugrel group; p=0.118), nor when considering the percent 
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difference (38±52% in the clopidogrel group vs. 42±98% in the prasugrel 
group; p=0.871). Considering the whole study population altogether, a 
significant correlation was found between IMR and PR both at baseline 
(r=0.458, p=0.003) and post-PCI (r=0.487, p=0.001) (Figure 38 panel A and 
B). A total of 24 patients showed a periprocedural increase in PR (15 in the 
clopidogrel group and 9 in the prasugrel group). In these patients, IMR post-
PCI was significantly higher compared with patients who did not show a 
periprocedural increase in PR (24.6±10.9 vs. 17.3±8.7, p=0.029) (Figure 38, 
panel C). In patients with periprocedural increase in PR, a significant 
correlation was found between ∆PR and ∆IMR (r=0.453, p=0.026) (Figure 
38, panel D). 
 
Figure 38: Microvascular function and platelet reactivity. Correlation between IMR and 
adenosine diphosphate-induced PR. Panel A: baseline. Panel B: post- PCI. Red dots indicate 
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patients in the clopidogrel group; blue dots indicate patients in the prasugrel group. 
Periprocedural variations of platelet reactivity and microvascular function. Panel C: IMR 
post-PCI in patients with and without periprocedural increase in adenosine diphosphate-
induced PR. Data shown as mean and standard deviation. Panel D: correlation between 
variations of PR (∆PR) and variations of IMR (∆IMR) in patients with periprocedural increase 
in PR.  Red dots indicate patients in the clopidogrel group; blue dots indicate patients in the 
prasugrel group. PCI: percutaneous coronary intervention; IMR: index of microvascular 
resistance; PR: platelet reactivity;  
 
Conclusions: a loading dose of prasugrel compared with clopidogrel is able 
to attenuate PCI-related increase in PR in patients with stable CAD 
undergoing PCI, which might contribute to the beneficial effect of this drug 
on peri-procedural coronary microvascular function.  
100 
 
Chapter 25 
Platelet reactivity in patients carrying the e-NOS G894T 
polymorphism after a loading dose of aspirin plus 
clopidogrel 
 
Background: Nitric oxide (NO) plays an important role in the modulation of 
PR through platelet recruitment, activation and aggregation. G894T single 
nucleotide polymorphism of eNOS gene results in the substitution of 
glutamic acid at codon 298 by aspartic acid. This substitution in the protein 
sequence is responsible of lower enzyme activity, i.e. lower NO production, 
and it has been associated with coronary spasm, atherosclerosis, MI, and 
stroke. Whether these adverse clinical events might be partly attributed to 
the modulation of platelet reactivity exerted by eNOS is still unknown. 
Aim: to assess the effect of G894T polymorphism on residual PR and on the 
risk of PMI in patients with stable CAD undergoing PCI and loaded with 
aspirin and clopidogrel at least 12 hours before, with a mean value of 8±2 
hours.  
Methods: A total of 632 patients with stable CAD undergoing elective PCI 
from October 2009 to December 2010 were retrospectively included. 
Exclusion criteria were upstream use of glycoprotein IIb/IIIa inhibitors, 
platelet count <70x10^9 /L, high bleeding risk (active internal bleeding, 
history of hemorrhagic stroke, intracranial neoplasm, arterial-venous 
malformation or aneurysm, ischemic stroke in the previous 3 months), 
surgery in the previous 3 months, and severe renal failure (serum creatinine 
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>2 mg/dl). All patients received at least 12 hours before PCI a dose of 500 
mg of aspirin and 600 mg of clopidogrel. To assess genotype with the 
TaqMan single nucleotide polymorphism Genotyping Assay (Applied 
Biosystems) and the platelet reactivity with VerifyNow test (Accumetrics) 
blood samples were collected from each patient at the moment of arterial 
puncture before angiography, whereas to evaluate the PMI, defined as an 
increase in TnT above the 99th percentile of a normal reference population 
[upper reference limit (URL)], further blood samples were collected at 24 
hours after PCI (Figure 39).  
 
Figure 39: Study design. ASA is aspirin. Pts is patients. PCI is percutaneous coronary 
intervention. 
 
Results: The observed genotype distribution for G894T, in Hardy-Weinberg 
equilibrium (p=0.56), was in the overall population as follows: homozygote 
G894G, n=263 (42%); heterozygote G894T, n=274 (43%); homozygote 
T894T, n=95 (15%). Analysis was conducted according to the dominant 
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model comparing Non Carriers (G894G: n=263 [42%]) versus Carriers of the 
894T allele (G894T+T894T: n=369 pts [58%]). We did not observe significant 
differences in clinical characteristics between the two groups, with the 
exception of previous PCI that was more frequent in Carriers (159 [43%] vs. 
89 [34%] in Non Carriers, p=0.02). Platelet reactivity values expressed as 
aspirin reactivity unit (ARU), P2Y12 reactivity unit (PRU) and platelet 
percentage inhibition were not different between groups as well as the HPR 
rate. 
Conclusions: we found neither increased PR nor a suboptimal response to 
dual antiplatelet therapy in CAD patients undergoing elective PCI and 
carrying the 894T genetic variant. Our findings clearly suggest that PR does 
not contribute to the association between the G894T polymorphism and 
the unfavourable cardiovascular outcome. 
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Chapter 26 
Correlation between serum uric acid levels and residual 
platelet reactivity in patients undergoing PCI 
 
Background: Uric acid has been demonstrated within atherosclerotic 
plaque, where it may predispose to thrombus formation by increasing 
platelet adhesiveness and by altering the normal platelet reactivity. 
Recurrent ischemic events and increased risk of stent thrombosis were 
reported in patients undergoing PCI in the presence of high residual PR 
despite treatment with dual DAPT with aspirin and P2Y12 inhibitors (e.g. 
Clopidogrel). The Novara Atherosclerosis Study (NAS) group has recently 
demonstrated that in patients on chronic DAPT after an ACS or an elective 
PCI, the serum uric acid levels (sUA) do not influence the response to 
platelet function at 30-90 days post-discharge. Yet, a large heterogeneity in 
platelet inhibition has been demonstrated just at the time of the PCI.  
Aim: to investigate whether sUA levels might have an impact on the rate of 
high PR. 
Methods: We investigated the association between sUA and high PR in 185 
patients with stable angina undergoing elective PCI. Blood samples were 
collected the day before PCI for sUA, and immediately after sheath 
insertion for platelet reactivity by VerifyNow P2Y12 assay (Accumetrics, San 
Diego, California) that was expressed as P2Y12 reaction units (PRU). High PR 
was defined as PRU ≥240. Hyper-uricemia was defined as sUA > 5.9 mg/dL. 
Patients were uniformly loaded with 500 mg ASA and 600 mg clopidogrel at 
104 
 
least 12 hours before PCI. Troponin T was measured before and 24 hours 
after percutaneous revascularization to assess PCI related myocardial 
damage (PMI=defined as 10 times TnT elevation). 
Results: Mean age of the patients was 68 ± 10 years, 72% (134/188 
patients) were males. Renal failure (GFR< 60 ml/min) was present in 26% 
(48/188) of the patients (mean GFR 71 ± 28.3 ml/min). The incidence of 
High PR was 39% (73/188 patients), while hyperuricemia was detected in 
56% (103/188) of the patients. Patients with elevated sUA showed a higher 
incidence of renal failure than patients without elevated sUA (p=0,034). No 
significant differences were observed for gender, smoking habits, diabetes, 
and age. No correlation was found between sUA and PRU (r= 0.135; p= 
0.084). PMI was detected in 6% (12/185) patients, with no significant 
difference between patients with and without elevated sUA (p=0,312). 
Conclusions: Our findings confirm and further extend the results from the 
NAS group demonstrating no association between sUA and high PR in 
patients undergoing PCI even in the peri-procedural phase. Moreover, we 
found that the association of high PR and elevated sUA does not predict 
PMI. 
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Chapter 27 
PROcedure related microvascular ACTIVation in long 
lEsions treated with bioresorbable vascular scaffold versus 
everolimus-eluting stent implantation (PROACTIVE trial) 
 
Background: Significant platelet activation has been observed with long 
stented coronary segments, despite ongoing anti-platelet therapy. This has 
been associated with peri-procedural microvascular impairment and 
myonecrosis probably secondary to distal embolization. Compared with 
DES, Bioresorbable vascular scaffolds (BVS) has different interaction with 
the vessel wall, mostly due to the fact that scaffold is made of poly-L-lactic 
acid (PLLA), with lower stiffness as compared with metallic stents. In 
addition, BVS is not associated with an increased compliance at the inflow 
segment, but conversely tended to decrease compliance at the outflow 
segment, therefore resulting into a potentially lower degree of compliance 
mismatch. It is not yet clear what might be the relative impact of the 
expected lower compliance vascular mismatch of BVS on microvascular 
function especially in relation to platelet inhibition during and after PCI. 
Given the inherent flexibility, we hypothesized that BVS Absorb™ might be 
associated with less platelet activation, thrombus formation and 
downstream microvascular impairment as compared with metallic EES 
Xience™ in stable patients undergoing PCI of long coronary stenoses. 
Aim: In long lesions treated either with everolimus-eluting bioresorbable 
vascular scaffold (BVS) or everolimus-eluting stent (EES), we sought to 
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investigate (a) procedure-related microvascular impairment, and (b) the 
relationship of platelet activation with microvascular function and related 
myonecrosis. 
Methods: The PROACTIVE study was a prospective randomized (1:1) open-
label superiority controlled trial in which 66 patients with stable coronary 
artery disease and long lesions (e.g. lesions to be treated with stent ≥ 25 
mm long) were enrolled. Exclusion criteria were: a) ACS; b) contraindication 
to DAPT; c) bifurcations with a side branch > 2.0 mm; d) need for rotational 
atherectomy; e) atrial fibrillation and treatment with oral anticoagulants. 
Primary endpoint was the difference between groups in changes of 
pressure-derived corrected index of microvascular resistance (cIMR) after 
PCI. CFR, FFR and peri-procedural myonecrosis by hs-cTnT were also 
evaluated. Platelet reactivity was assessed by high-sensitivity adenosine 
diphosphate (hs-ADP)-induced platelet reactivity with the Multiplate 
Analyzer™ before, after PCI, then at 24 hours and at 30 days follow up. 
Results: 66 patients were enrolled in this trial: 33 randomized to BVS 
Absorb™, and 33 to EES Xience Xpedition™ or Xience Alpine™ implantation. 
Baseline clinical characteristics were not different between the 2 groups. 
No in-hospital major adverse events occurred. No differences between the 
two groups in terms of number of vessel diseased, vessels and Syntax 
segments treated as well as complexity of the lesions defined according to 
the ACC/AHA classification of coronary lesions were observed. Semi-
compliant balloons were more frequently used in patients treated with EES 
implantation, although there were no significant differences between the 
two group in terms of lesion preparation, as well as for maximum and 
minimum stent/scaffold diameter, number of stent/scaffolds implanted per 
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patient and total stent/scaffold length. As expected by recommendations, 
post-dilatation was more frequently performed in patients treated with BVS 
implantation, with associated longer procedure time in these patients. 
However, in the stent/scaffold optimization, no difference between the two 
groups have been observed regarding use of semi-compliant and non-
compliant balloon, maximal diameter balloon, maximal pressure and total 
time of balloon inflation. No significant between groups differences were 
observed in FFR, CFR and cIMR both before and after-PCI. Yet, a significant 
difference in cIMR was observed within the BVS group after PCI versus 
baseline (19 ± 8 vs. 24 ± 12, p= 0.04), but not in the EES group (21 ± 9 vs. 21 
± 13, p= 0.84 (Figure 40). A significant difference in the primary endpoint of 
ΔcIMR was observed between the 2 groups (EES group -0,3 ± 13,6 vs. BVS 
group -4,7 ± 13,2; p= 0,04) (Figure 41).  
 
Figure 40: Changes in cIMR after PCI in the two group. Left panel: patients treated with EES - 
Xience; right panel: patients treated with BVS – Absorb. cIMR: corrected index of 
microvascular resistance. 
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Figure 41: Difference between the two groups in ΔcIMR. Significant difference between the 
two groups in the primary endpoint, in favor of the BVS group. ΔcIMR: delta corrected index 
of microvascular resistance. 
 
A significant reduction of hs-ADP was observed after PCI in both EES (hs-
ADP: pre-PCI 18,4 ± 9,3 AU vs post-PCI 6,7 ± 4,8 AU; p < 0,0001) and BVS 
group (hs-ADP: pre-PCI 21,6 ± 11,1 AU vs post-PCI 13,8 ± 7,2 AU; p < 0,0001) 
without any difference between the two groups at baseline, post-PCI  and 
at 30 days follow-up. Also no consistent trends of hs-ADP values across the 
three main time of measurements up to 30 days follow-up has been 
detected (ANOVA for trend p= 0,29). Hs-cTnT significantly increased in both 
groups after PCI (EES: hs-cTnT pre-PCI 11,4 ± 13,3 ng/L vs hs-cTnT post-PCI 
84,9 ± 195,2 ng/L; p<0,0001. BRS: hs-cTnT pre-PCI 10,7 ± 16,1 ng/L vs hs-
cTnT post-PCI 104,2 ± 182 ng/L; p<0,0001), without difference at baseline 
and after PCI between the two groups. Also no significant difference in 
terms of ∆hs-cTnT between EES and BVS group has been observed (∆hs-
cTnT EES group 73,4 ± 195,1 vs ∆hs-cTnT BRS group 93,4 ± 185,3; p= 0,38). 
Conclusions: In long lesions, BVS implantation is associated with a 
significant reduction in cIMR as compared with EES. The limited acute 
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impact of BVS on the microcirculation effect is associated with an optimal 
peri-procedural and short-term platelet inhibition, without significant 
difference in peri-procedural myonecrosis as compared with patients 
treated with EES. 
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Part VI 
 
Percutaneous coronary interventions in 
bifurcation lesions: from bench tests to 
clinical outcome 
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Chapter 28 
Single String Technique for stenting of complex coronary 
bifurcation stenoses 
 
Background: For more complex bifurcations pathologies, in which an 
important side branch (SB) is involved or stenosed over a longer segment 
(more than 5 mm, starting at its ostium), the single stent strategy may not 
provide optimal results with adequate downstream flow in both territories. 
A wide variety of techniques using 2 regular stents hasbeen described and 
evaluated including T-, culotte, crush, minicrush, T- and protrusion stenting, 
but the best choice remains unclear. The main limitations of each of these 
techniques are due to superimposition of multiple metal layers and 
frequent stent strut malapposition.  
Aim: The study aims to evaluate the clinical applicability of the single-string 
bifurcation stenting technique, developed to optimise PCI of complex 
bifurcation stenoses with respect to maximal wall coverage and to minimise 
multiple strut layers. 
Methods: Single string is a novel double-stent bifurcation stenting method 
previously described (JACC Cardiovasc Interv. 2015), where first the SB 
stent is deployed with one single stent cell protruding into the main branch 
(MB). Second, the MB stent is deployed across this protruding stent cell. 
The procedure is completed by final kissing balloon dilation (Figure 42). 
Patients with true bifurcation lesions, involving at least 1 of the MB 
segments plus the SB, with SB stenosis extending for ≥ 5 mm, were selected 
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for single string procedure. The PCI procedure was performed according to 
the standardized protocol and procedural steps as described. Various stent 
brands were used: selection criterion was to have uniformly large cells of a 
minimum of 4.4-mm maximal cell expansion diameter. 
 
Figure 42: Guidewires are indicated as ‘master-gw’ (highlighted in red) and ‘fellow-gw’ 
(highlighted in blue). Master-gw is advanced into the SB, and the fellow-gw into the MB (A). 
Stent is deployed in the SB with careful positioning of its proximal edge at the rim of the 
ostium, resulting in a single string of stent strut protruding into the MB (B). The stent is 
proximally optimized (C). The master-gw is pulled back and readvanced through the 
protruding single string cell into the MB (D). Single string cell is opened up with a balloon 
(E,F). MB stent is positioned and deployed through the single-string cell, over the master-gw 
(G). Master-gw is advanced into the SB, crossing the most distal cell of the MB stent in the 
SB ostium, and fellow-gw is positioned into the MB. Sequential final kissing balloon dilation 
is performed as appropriate (H). Final result is indicated in (I). gw = guidewire; MB = main-
branch; SB = side-branch. 
 
Results: In this study, the single-string technique was applied in 35 
consecutive patients with complex bifurcation stenoses with indication for 
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intended double stenting. Thirty-four lesions (94%) were located in the LAD, 
while 1 lesion (6%) was in the left circumflex. SB was significantly stenosed 
in 33 cases (94%), while 17 (49%) lesions were classified as true Medina 
1,1,1 lesion. All procedures were performed successfully. For the 
procedure, 2.6±0.6 guidewires and 4.9±1.7 balloons were used. Duration 
was 105+32 minutes, while 294±84 mL contrast media was injected. A good 
angiographic result was achieved in all cases with a final residual diameter 
stenosis of 11±8% in the MB and 13±9% in the SB, measured by QCA. 
Results of extensive procedural optical coherence tomography (OCT) 
imaging will be available. During follow-up of 15±9 months, one major 
adverse cardiac event (early SB occlusion in a clopidogrel non-responder 
patient) was observed (3%). 
Conclusions: The single-string bifurcation stenting technique is shown to be 
feasible for the treatment of complex bifurcation lesions with favourable 
long-term results. 
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Chapter 29 
Reversed single string technique for coronary bifurcation 
stenting - First report of case demonstrations in vitro 
 
Background: in a non-negligible proportion of bifurcation lesions, stenting 
of the SB becomes necessary at the end of PCI due to marked carina shift or 
dissection. The potential solutions that are currently available for securing 
the SB in such cases (for instance T-stenting, T-and-Protrusion, Reversed 
Crush, or Reversed Culotte) are all having limitations in terms of 
superimposition of multiple metallic layers, incomplete ostial coverage, or 
frequent stent strut malapposition. Single String technique appears to offer 
the best compromise between perfect strut coverage of the whole 
bifurcation area with minimal overlap of one single string of strut.  
Aim: Based on the principle of Single String technique we sought to 
introduce a potential novel bail out strategy for provisional T stenting, 
when the result in the SB is suboptimal and requires stenting. In this proof-
of-concept report, we describe the procedural steps of the Reversed Single 
String technique, illustrated with in vitro procedures. 
Methods: The presented Reversed Single String stenting procedures were 
performed using guidewires (Balance Middleweight, Abott vascular, IL), 
semi-compliant balloons (Sprinter legend, Medtronic, Dublin, Ireland), and 
Ultimaster™ drug-eluting stents (Terumo Corporation, Tokyo, Japan) in size 
of 2.5 mm and 3.0 mm. Procedures were started with state-of-the-art 
provisional T-stenting technique: (1) a 3.0 mm stent was deployed in the 
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MB, then (2) proximal MB was optimized with a 3.5 mm 3 8 mm non-
compliant balloons (Emerge, Boston Scientific, Galway, Ireland), and (3) 
finalized with kissing balloon dilation, using 3.0 mm and 2.5 mm balloons in 
the MB and the SB, respectively. Simulating real life scenarios, performing 
Reversed Single String technique can be indicated at this point, if the result 
in the SB is suboptimal (Fig. 43A). For educational reasons we call the two 
guidewires (gw), we use as “master-gw” (being in the MB—highlighted in 
red in Fig. 43) and “fellow-gw” (being in the SB—highlighted in blue in Fig. 
43). (1) As first step, over the “fellow-gw” a 2.5 mm stent was deployed (12 
bars) with careful positioning of its proximal edge at the proximal rim of the 
SB ostium. That resulted in no more than a single string of stent strut 
protruding into the MB (Fig. 43B). (2) Proximal optimization was done by 
reinflation of the stent delivery balloon at higher pressures (16 bars) after 
partial pullback (Fig. 43C). (3) Next the “fellow-gw” is slowly pulled back 
until it falls into the protruding cell, through which it was advanced into the 
distal MB (Fig. 43D). (4) The protruding cell was opened up to reasonable 
size with a 2.5 mm balloon, or a 1.5 mm balloon when needed (Fig. 43E). (5) 
“Master-gw” was pulled back and positioned in the SB. (6) Kissing balloon 
dilation was performed using 3.0 mm and 2.5 mm balloons in the MB and 
the SB, respectively (Fig. 43F). Finalized with proximal MB optimization with 
a 3.5 mm 3 8 mm non-compliant balloon. Schematic illustration of the final 
result is shown in Fig. 43G–I. 
116 
 
 
Figure 43: Schematic image depicting the steps of the Reverse Single String bifurcation 
stenting technique. See detailed description in the main text. 
 
Optical frequency domain imaging (OFDI) imaging was done in each case. 
Note that OFDI pullback was considered as final step, meaning no further 
action was taken based on its results. For descriptive purposes, analysis of 
the imaging data was performed by dividing each bifurcation into six 
different areas, as shown in Fig. 44. Malapposition of stent struts was 
calculated and graded as (1) incomplete apposition (malapposition >0 µm), 
(2) marked malapposition (malapposition >200 µm), and (3) floating struts 
(malapposition >500 µm). 3D reconstruction was visually evaluated to 
describe potential strut fracture or strut expansion. 
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Figure 44: Silicone phantoms, used for in vitro testing. For didactical reasons bifurcation was 
divided into six sectors, when evaluating OFDI images. These sectors were as follows: 
proximal MB (1, blue), proximal bifurcation ostial half (2, light red), proximal bifurcation 
abostial half (3, dark red), distal bifurcation ostial half (4, yellow), distal bifurcation abostial 
half (5, orange), distal main branch (6, purple). 
 
Results: All three in vitro procedures were successfully performed 
according to the protocol, with excellent result by fluoroscopy (Figure 45A). 
OFDI analyses were completed in each case. Procedure duration was 30, 25, 
and 22 minutes in Cases #1 to #3, respectively. Fluoroscopy time was 1.9, 
2.4, and 1.8 minutes in Cases #1 to #3, respectively. In all three cases the 
initially chosen workhorse guidewires allowed to complete the procedure 
and one additional, small sized balloon was needed for predilating the 
string cell and for predilating the SB ostium before final kissing dilation.  
OFDI was performed in all three cases (Case #1, #2, and #3). Struts were 
fully apposed in 79.0, 89.0, and 75.9% overall, respectively. When focusing 
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on the bifurcation areas alone (areas #2–5, as shown on Fig. 45), 
malapposition occurred in 1.5, 1.8, 17.0%, and floating struts were 
observed in 2.2, 0.0, 0.0% in the bifurcation areas of Cases #1, #2 and # 3, 
respectively. Malapposition was most frequently seen in the distal ostial 
area, namely where a neo-carina might have been created (area #4; 1.4, 
0.0, 32.0% of Cases #1, #2, and # 3 respectively), less frequently observed in 
the proximal ostial area (area #2; 0.0, 0.0, 5.7% of Cases #1, #2, and # 3, 
respectively) and rarely found in other segments. No marked malapposition 
was observed in the side branch neither in the distal main branch (area #6). 
3D reconstruction allowed exact evaluation of strut structure. Visual 
analysis did not reveal any strut rupture (Fig. 45B, left panel). Detailed 
visual inspection of the 3D reconstructed images suggests no marked loss in 
wall coverage (strut to wall surface ratio in all phantoms) in the ostial SB 
area, where the stent strut structure is mostly affected by the forces in the 
string strut (Fig. 45B, right panel).  
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Figure 45: A) X-Ray. High-resolution fluoroscopic image offers excellent opportunity to 
evaluate the final result. B) 3D reconstructed OFDI. Pullback image in the main branch is 
shown in the left panel. In the right panel, pullback image in the ostial side branch is shown. 
In the lower schematic panels, the main branch stent is indicated in light blue, the side 
branch stent is indicated in red. The longitudinal pullback image is shown in the lower panel 
with the string strut within the red circle. See further explanation in the main text. 
 
Conclusions: Although most provisional T stenting cases can be completed 
with one single main branch stent, there is a non-negligible portion of cases 
where the side branch eventually requires stenting. In this proof-of-concept 
report, Reversed Single String bifurcation technique was shown to be 
feasible, offering a potential bail out solution for such clinical scenarios. 
Clinical effectiveness remains to be confirmed in real clinical conditions. 
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Chapter 30 
Resorbable magnesium scaffold in coronary bifurcations - 
report of in vitro experiments 
 
Background: As coronary bifurcations represent 10-15% of all PCIs, it is 
crucial to understand whether and to what extent bioresorbable scaffolds 
are applicable in these rather common complex lesions. Due to marked 
variability in terms of distribution of atherosclerosic plaque, in terms of 
main branch and side branch calibers and in terms of their angulation, there 
is necessarily a significant discrepancy between the pure tubular shape of a 
stent and individual bifurcation anatomy. All currently widely accepted 
single- and double-stent techniques aim to address these variations, 
sometimes requiring a massive deformation of the original strut structure. 
While the behavior and performance of conventional metallic stents have 
been thoroughly investigated in vitro, as well as in vivo, our knowledge is 
still limited about bioresorbable vascular scaffolds, especially new 
technologies such as the resorbable magnesium scaffold (RMS) (Magmaris; 
Biotronik AG, Bülach, Switzerland). 
Aim: The aim of the present work is to evaluate extensively in an in vitro 
setting the behavior of RMS in various non-bifurcation and bifurcation 
anatomies using standard interventional techniques. 
Methods: Performance was evaluated in vitro with focus on vessel 
tortuosity and on bifurcations. All the tests were performed using 3.50x25 
mm RMS in 3D printed, pure saline-filled silicone vessel phantoms. 
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Procedures were performed under conventional fluoroscopic guidance. 
Results were evaluated by (1) fluoroscopy, (2) OCT and (3) micro-computed 
tomography (μCT), in terms of scaffold conformability, strut apposition, 
structural deformation and strut fracture. Procedural performance (i.e. 
cross-ability of a guidewire or a balloon to the side branch) was described 
subjectively by the operator. In order to test the performance of RMS in 
tortuous anatomies, procedures were performed in a 90° bent silicone 
vessel model with 3.50 mm inner diameter. First, the RMS was implanted 
within the curve at a dilatation pressure of 12 atm. Secondly, the entire 
length of the scaffold was post-dilated with a 3.50x15 mm non-compliant 
balloon at 12 atm with multiple inflations. For bifurcations, procedures 
were performed in two types of uniform silicone bifurcation models, where 
proximal MB, distal MB and SB were 3.50/3.00/2.50 mm in diameter 
(Model #1), and 4.00 mm/3.50 mm/3.00 mm in diameter (Model #2), 
respectively. Angulation between distal MB and SB was uniformly 60°. 
Procedures were performed in five different ways, (1) MB stenting with SB 
opening and proximal optimization; for (2) MB stenting with final kissing 
and proximal optimization; for (3) T-and-protrusion technique; for (4) string 
technique. All tests were performed using 3.50x25 mm RMS. 
Results: All procedures were successfully performed according to the 
protocol, as described above. No unexpected difficulty was described at any 
of the procedures. RMSs were advanced easily through markedly bent 
anatomies, as well as to MB and to side branches. Operators did not 
describe any unexpected difficulty of guide wire or balloon crossing to the 
jailed SB. Subjectively the performance of the RMSs was comparable to 
experiences with conventional permanent metallic stents. 
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In tortuous vessels (n=3) altogether 1470 scaffold struts were analyzed in 
138 OCT frames. After initial scaffolding, the malapposition rates were 
1.0%, 1.7% and 3.2% over the three cases. Post-dilation led to marked 
reduction, resulting in malapposition rates of as low as 0.0%, 0.4% and 
0.4%, respectively. Note, that no strut with marked malapposition was 
observed at any phases. Malapposition was mainly seen in the middle 
portion of the stent, namely where the bending of the vessel is the most 
pronounced. Visual evaluation of the μCT images suggests that circular 
cross-section has been preserved along the bend. No relevant flattening 
tendency has been observed at any points of the bend, as illustrated on the 
example case depicted in Figure 46. 
 
Figure 46: Bench setting for tortuose vessel. Fluoroscopy (left) and 3D-reconstructed μCT 
image (right) for visual evaluation of RMSs’ performance. 
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In bifurcations cases the overall malapposition rate at OCT was 4.3%, 
occurring predominantly in the carinal area. No malapposition was seen at 
the proximal MB confirming proper conformability of RMS. μCT analysis has 
shown that final kissing dilation resulted in fully stretched struts in cases, 
where performed with 3.5 and 3.0 mm balloons (Figure 47). Accordingly in 
one case a broken connector (T-and-protrusion) and in another case, a 
broken strut (String technique) were identified (Figure 48). 
 
Figure 47: Bench setting for bifurcation PCI. 1) Main branch scaffolding with side branch 
opening alone – small side branch. 2) Main branch scaffolding and final kissing dilation – 
small side branch. 3) Main branch scaffolding and final kissing dilation – large side branch. 4) 
T-and-Protrusion technique – large side branch. A and B panels indicate longitudinal luminal 
views from distal main branch and distal side branch, respectively. 5) Single string technique 
– large side branch. A and B panels indicate longitudinal luminal views from distal main 
branch and distal side branch, respectively. In all the panels: Fluoroscopy (left) and 3D-
reconstructed μCT image (right) for visual evaluation of RMSs’ performance.   
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Figura 48: Scaffold fractures. Fluoroscopy (left) and 3D-reconstructed μCT images (right) of a 
T-and-Protrusion case (A) and a Single string technique case (B), where careful μCT analysis 
identified a connector fracture and a strut fracture, respectively. 
 
Conclusions: Latest generation resorbable magnesium scaffolds can 
structurally cope with bifurcations in various in vitro models. Still, for cases 
(i.e. large diameter step down, large side branches, etc.) and techniques 
(culotte, string, etc.) where massive overexpansion of the scaffold (i.e. the 
lumen or any cell) is needed, RMS might not be the proper device due to a 
definite risk of strut fracture. This investigation may justify future clinical 
evaluation of the device in complex coronary anatomies using standardized 
procedural techniques. 
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Chapter 31 
Mid-term outcomes after percutaneous interventions in 
coronary bifurcations 
 
Background: Despite the major progress in stent technologies and 
adjunctive pharmacotherapies, the treatment of bifurcations is still 
challenging, as it is associated with worse outcomes when compared with 
non-bifurcation lesions. Although the single stent strategy is associated 
with a reduced risk of untoward events and is currently recommended, the 
double stent strategy may be required to guarantee the patency of both the 
main vessel and SB. In addition, it is unclear whether the clinical outcomes 
of PCI in bifurcations can be modulated by the choice of adjunctive P2Y12 
inhibitor, the optimal DAPT, as well as the selection of the stent platform. 
Aim: to investigate the major clinical, anatomic and procedural 
determinants of mid-term clinical outcomes in all comer patient population 
undergoing PCI in bifurcations. 
Methods: The P2BiTO (P2Y12 inhibitor utilization in Bifurcation and Chronic 
Total Occlusion percutaneous coronary intervention with biologically active 
stents) registry was a retrospective multicenter registry in which 17 major 
coronary intervention centers in Europe and abroad participated, with the 
endorsement of the EuroBifurcation Club. Data were collected on 
consecutive patients who underwent PCI with “biologically active”, either 
DES or BVS, on a coronary bifurcation between January 2012 and December 
2014. Inclusion criteria were: (1) patients aged ≥18 years with a diagnosis of 
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stable CAD or ACS; (2) PCI of a bifurcating lesion (all Medina types) with 
single or multiple “biologically active” stents (DES or BVS) at participating 
centers; and (3) main vessel diameter ≥2.5 mm and SB diameter ≥2.0 mm. 
Exclusion criteria were: (a) Patients who refused informed consent or with a 
life expectancy of ≤12 months; (b) pregnant or nursing mothers; women of 
child-bearing age will be asked if they are pregnant or think that they may 
be pregnant; (c) contraindication or suspected intolerance to anticoagulant 
(heparin, bivalirudin) or oral antiplatelet therapy (aspirin, clopidogrel, 
prasugrel, ticagrelor); (d) absence of bifurcation lesion or unwillingness to 
treat with PCI any of them. A loading dose of clopidogrel (600 mg), 
prasugrel (60 mg), or ticagrelor (180 mg) was administered before or 
immediately after PCI, unless patients were already on chronic 
maintenance therapy, followed by a maintenance dose of clopidogrel (75 
mg od), prasugrel (10 mg od), or ticagrelor (90 mg bid).  
The primary endpoint of the study was the cumulative occurrence of Major 
Adverse Cardiac Cerebrovascular Events (MACCE), defined as a composite 
of death (cardiac and noncardiac), nonfatal myocardial infarction (MI), stent 
thrombosis and stroke during the follow-up; the secondary endpoints were 
the single occurrence of death, MI, stent thrombosis and stroke. 
Results: Among the 5,036 patients who underwent DES- or BVS-PCI on a 
coronary bifurcation, 639 (12.7%) in-hospital adverse events were reported: 
death in 53 cases (1.1%), periprocedural MI in 584 (11.6%), stroke in 28 
(0.55%) and stent thrombosis in 50 cases (1.0%). Follow-up was available in 
4,506 patients (89%). At a 18 months median (IQR 11-28) follow-up, the 
primary endpoint occurred in 453 (10%) patients: death in 235 cases (5.2%), 
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MI in 156 (3.5%), stroke in 75 (1.7%) and stent thrombosis in 110 cases 
(2.4%) (Fig. 49).  
 
Figure 49: Cumulative incidence proportion of the primary and secondary endpoints. 
MACCE= major adverse cardiac and cerebrovascular events, MI= myocardial infarction. 
 
Patients who experienced MACCE at follow-up were older, with a higher 
prevalence of diabetes, hypertension, prior MI, CABG and stroke, low 
(≤30%) LVEF and were more frequently admitted for an ACS. Also the latter 
higher prevalence of in-stent restenosis, more extensive CAD, longer lesions 
in both MB and SB, and a higher Syntax score; they more frequently 
received a BVS as compared with a DES, double stenting, an additional stent 
in bail-out, a higher total stent length and more frequently discontinued 
DAPT prematurely. The treatment of a left main and a planned strategy of 
double stenting as compared with planned single stent, showed only a 
trend towards an increased risk of the primary endpoint, but were 
significantly associated with increased mortality. 
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When analyzing the relevance of clinical presentation and angiographic 
morphology, ACS was a major risk factor for MACCE regardless the 
presence of a “true” Medina lesion (Fig. 50), while when taking into account 
the SB stenosis length, patients with stable CAD and SB lesion < 9 mm 
showed the lowest risk of MACCE (Fig. 51). 
 
Figure 50: Cumulative incidence proportion of major adverse cardiac and cerebrovascular 
events (MACCE) stratified according to clinical presentation and Medina classification. 
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Figure 51: Cumulative incidence proportion of major adverse cardiac and cerebrovascular 
events (MACCE) stratified according to the lesion length of the side branch (SB) lesion.  
 
As for stent strategy, a single “provisional” stent was used in 4,284 patients 
(85.1%), double stenting in 525 cases (10,4%), as planned. An additional 
stent was deployed as “bail-out” in 227 patients (4.5%), in the setting of a 
provisional stent strategy in 194 (4.3%), after double stenting in 33 (5.9%, 
P<0.05) cases. Main reasons for bail-out stenting were dissection of MB or 
SB (85, 37%), plaque shift (93, 41%), unsatisfactory result (34, 15%) or 
geographical miss (15, 7%). As for mid-term outcomes, while among 
patients receiving a planned strategy there was a trend favoring single as 
compared with double stenting, placement of an adjunctive stent in bail-
out in the setting of a single provisional approach was associated with a 
higher incidence of MACCE than double stenting without any other stent in 
bail-out (Fig. 52). The Cox proportional hazard regression analysis 
documented that LVD, older age, a longer SB lesion length, the presence of 
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ACS at admission, bail-out stenting and diabetes were independent risk 
factors for MACCE.  
 
Figure 52: Cumulative incidence proportion of major adverse cardiac and cerebrovascular 
events (MACCE) stratified according to stent strategy. 
 
Conclusions: In patients undergoing PCI of a coronary bifurcation with 
currently available drug and stent technology, clinical variables, such as 
older age, diabetes, clinical presentation with an ACS and reduced LVEF are 
independent predictors of mid-term untoward events. Moreover, 
treatment strategy must be carefully planned, as length of the SB lesion and 
“bail-out” stenting are independent predictors of adverse events. 
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Part VII 
 
Discussion and conclusions 
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Discussion 
 
Part I. From pressure derived-FFR to Absolute Flow and Microvascular 
Resistance 
Since its first description(7-9), FFR is considered the standard of reference for 
evaluation of the ischemic potential of coronary stenoses and the expected 
benefit from revascularization(12-15,38,39). Because FFR-based decisions are 
important for patients’ outcomes, and given the need for rigor and 
reproducibility in reading the tracings by core laboratories, the highest 
technical quality of FFR measurements is desirable. We therefore proposed 
a standardization document (chapter 2) for acquiring, recording, 
interpreting, and archiving the pressure tracings for daily practice and for 
the purpose of clinical research involving a core laboratory. We believe that 
the benefit of FFR-guided revascularization strategies can be optimized 
when FFR measurement and analysis are performed in a rigorous and 
standardized manner(40). In this work we aimed also at standardize the 
dosage of hyperemic agents. Administration of intravenous adenosine 
provides reliably stable maximal hyperemia, maintainable for minutes, 
when indicated. Therefore, in daily practice, it is to be applied when IC 
administration is difficult (e.g., in case of ostial stenosis) or when pullback 
measurements have to be performed (e.g., for the evaluation of serial 
stenosis), at the recommended dose is 140 µg/kg of body weight/min. 
Maximal hyperemia can be similarly induced by IC administration of 
adenosine. The degree of vasodilation is very similar and the FFR values are 
comparable to those obtained with IV. The test/retest repeatability tends to 
be better with IC than with IV administration of adenosine. We performed a 
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dose-response study (chapter 3) to establish the dosage of IC adenosine 
associated with minimal side effects and above which no further increase in 
flow can be expected. The analysis have shown that 100 µg in the right 
coronary artery and 200 µg in the left coronary artery reliably and 
reproducibly achieve >95% of maximum hyperemia without any significant 
side effects. The hyperemic effect of these doses is clinically 
indistinguishable from higher dosages, but with a lower rate of atrio-
ventricular block; thus, there is no reason to use higher dosages(41).  
In a complete accidental manner we have discovered, and subsequently 
tested, that even IC infusion of saline at room temperature is able to induce 
hyperemia. While performing measurements of minimal microvascular 
resistance in patients with mild atherosclerosis, we observed the 
occurrence or the increase of a pressure gradient between the coronary 
ostium and the distal part of the coronary artery few seconds after the start 
of the IC infusion of saline, even before the start of adenosine infusion. In 
order to prove this, we performed in 24 patients intracoronary doppler flow 
velocity measurements at rest, after IC adenosine, and during increasing 
infusion rates (5, 10, 15, and 20 mL/min) of saline at room temperature 
through the RayFlow™ catheter, a dedicated catheter for coronary 
thermodilution with 4 lateral side holes (chapter 4). We have also observed 
that the IC saline infusion does not affect blood pressure, systolic, or 
diastolic left ventricular function. The mechanisms by which the 
administration of saline through the side holes of the catheter in proximal 
epicardial segments induces vasodilation of downstream resistance arteries 
remain speculative and are probably multifactorial. We think that the 
stimulation of the proximal part of the coronary artery by the 4 small jets of 
saline at ≈34°C hitting the vascular wall appears central to the hyperemic 
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effect. Indeed, this phenomenon was weak and inconsistent when saline 
was given through the distal opening of an infusion catheter. Endothelial 
production of nitric oxide (NO) can be triggered by mechanical deformation 
resulting from shear forces or pulsatile strain caused by blood flow(42) and 
NO-dependent mechanisms contribute in a positive feedforward control to 
hyperemia during exercise in animals(43,44). Endothelial cells can also release 
other vasoactive compounds, such as prostanoids, endothelin, and 
endothelium-derived hyperpolarizing factor(45,46). Yet, their exact role on 
human microvasculature remains largely unknown, as is their stimulation 
by mechanical forces or changes in temperature. The fact that adding IV 
adenosine infusion to saline infusion through the RayFlow™ catheter does 
not increase coronary flow suggests that the pathway to induce coronary 
hyperemia is similar, or that saline infusion overrides many different 
pathways through which coronary vasodilation occurs. Finally, hyperemia 
seems to be strictly localized to the coronary artery in which saline is 
infused, as we did not observe any crosstalk between different myocardial 
beds.  
These findings have definitively opened a new scenario in terms of 
microcirculatory assessment of flow and resistences using the RayFlow™ 
catheter, avoiding any specific pharmacological microvascular vasodilator, 
like adenosine. We therefore carried out a first-in-man study on 135 
patients in order to test the feasibility, safety, and reproducibility of the 
continuous thermodilution method for the absolute coronary blood Flow 
and microvascular Resistance (chapter 6). The feasibility of the method was 
described 10 years ago, but the technique has been hampered by the 
absence of an appropriate monorail infusion catheter, the need for 
additional intravenous adenosine, and the absence of suitable software. 
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Now, all 3 issues have been solved: the RayFlow™ catheter allows the 
appropriate infusion of saline, there is no need for additional adenosine 
because the saline infusion induces hyperemia, and dedicated software for 
calculating Q and R online has been developed. Therefore, the procedure 
has become easy, taking ≈5 minutes including the 60 seconds of infusion of 
saline at room temperature, once the GC, the pressure/temperature wire, 
the RayFlow™ catheter, and the pump with saline are all set. The safety was 
confirmed by the absence of any significant complications (only 8% of the 
patients experienced transient bradycardia and concomitant 
atrioventricular block) and the duplicate measurements in a subgroup of 80 
patients showed an high test-retest reproducibility(36).  
 
Part II. Fractional flow reserve and natural history of stable coronary 
artery disease 
FFR was initially validated against composite information from sequentially 
performed noninvasive tests(10,11,47). It was shown that, below the value of 
0.75, epicardial stenoses were associated with 100% positive predictive 
value for stress-inducible myocardial ischemia, whereas an FFR value >0.80 
has a negative predictive value of >95%(10). The DEFER trial indicated that 
PCI of coronary stenoses with FFR values >0.75 did not improve clinical 
outcome in comparison with patients deferred to optimal medical therapy 
(OMT)(38). However in a minority of patients, an FFR value between 0.75 and 
0.80 was found to be associated with typical exercise-induced angina and 
reversible flow maldistributions(47). Therefore, in the era of DES, the 
threshold of 0.80 was adopted in subsequent studies(13,39) and in clinical 
practice, as well. FFR values between 0.75 and 0.80 have been referred to 
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as the FFR gray zone, alluding to some uncertainty regarding the degree of 
ischemia present related to the stenosis being interrogated. Based on this 
lack of evidences, we aimed at investigate the MACE (death, MI, and any 
revascularization) up to 5 years of 1459 patients with single-segment 
disease and an FFR value within the gray zone or within the 2 neighboring 
FFR strata (0.70–0.75 and 0.81–0.85), treated with PCI vs. OMT (chapter 7). 
In patients undergoing OMT, a progressive increase in MACE rate was 
observed when going from the highest FFR stratum of 0.81 to 0.85 to the 
lowest FFR stratum of 0.70 to 0.75. Even within the range of 0.70 to 0.85, 
the lower the FFR value, the higher the event rate. This result not only 
confirms the value of the 0.80 threshold, but also narrows the gray zone for 
clinical decision making: stenoses with an FFR <0.80 deserve 
revascularization, whereas stenoses with an FFR >0.80 are better treated 
with OMT, even though this dichotomy should obviously be nuanced by the 
morphological characteristics of the stenosis and the clinical context of the 
patient. These data are in line with the recent meta-analysis of Johnson et 
al. indicating a linear relationship between FFR values and clinical 
outcome(48). Consistently, among 607 patients of the FAME 2 trial with 
documented stable CAD and in whom no revascularization was performed, 
we compared the respective values of angiographic diameter stenosis and 
FFR in predicting natural history (chapter 9). The primary end point, defined 
as vessel-oriented clinical end point (VOCE) at 2 years, was a composite of 
prospectively adjudicated cardiac death, vessel-related myocardial 
infarction, vessel-related urgent, and not urgent revascularization. The 
stenoses were divided into 4 groups according to FFR and %DS values: 
positive concordance (FFR≤0.80; DS≥50%), negative concordance 
(FFR>0.80; DS<50%), positive mismatch (FFR≤0.80; DS<50%), and negative 
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mismatch (FFR>0.80; DS≥50%). There was no significant difference in VOCE 
between the positive concordance and positive mismatch groups (p= 0.149) 
and no significant difference in rate of VOCE between the negative 
mismatch and negative concordance groups (p= 0.067)(49). The data indicate 
that the FFR value predicts the natural history significantly better than DS, 
suggesting that “physiology trumps anatomy”(50). In addition, among the 
stenoses with mismatch between DS and FFR, >50% had a low FFR in the 
presence of an angiographically mild stenosis. This relatively high rate of 
discordance (mismatch) between anatomy and physiology is actually not 
surprising because it relates to many different factors. First, there are a 
number of specific reasons, such as inaccuracy of border detection, 
foreshortening of the stenotic segment, superimposition of side branches, 
asymmetry of the stenotic segment, and inaccuracies of the pressure 
measurements. Second, cutoff values of both DS and FFR are surrounded by 
a grey zone. However, the most important reason for the disconnect 
between anatomy and physiology relates to the myocardial mass that 
depends on the stenosis and vasodilatory capacity of the vascular bed. The 
reference diameter partially accounts for the myocardial mass. This is the 
reason that the optimal cutoff value for DS decreases when the diameter of 
the vessel increases, typically in left main and proximal left anterior 
descending artery(5,51). We think that FFR measurements should no longer 
be limited to angiographically intermediate stenosis but should be 
contemplated in stenoses that are mild or severe by visual evaluation.  
On the way of the risk continuum between FFR and outcomes, we 
retrospectively explored the natural history of 414 intermediate stenoses 
from 331 patients with consecutive FFR measurements at least 6 months 
apart (chapter 10). We found that FFR regresses at a slow rate (median 
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∆FFR= 0.007 per year). As a consequence, only 1 out of 4 lesions had a 
significant FFR worsening over a two-year period. The slow decline in FFR in 
our cohort was paralleled with a slow increase in stenosis severity 
measured by QCA. Despite the similar slow deterioration in both FFR and 
%DS, these metrics should not be used interchangeably to gauge clinical 
information. This is reflected in the very weak, albeit statistically significant, 
correlation of their rates of change in our cohort. “Baseline FFR”, but not 
angiographic indices, is an independent predictor of significant longitudinal 
atherosclerosis progression, predicting which lesions will require 
revascularization(52). 
 
Part III. Fractional flow reserve in special clinical settings 
FFR has many useful features: 1) a unique and validated cut-off value set at 
0.80(13-15); 2) a reliable hyperemic response of the microcirculation once 
maximal hyperemia is induced(41); 3) a complete independence from all 
hemodynamic changes (blood pressure, heart rate, and contractility)(53,54). 
Still there are some potential technical pitfalls and drawback setting that 
we decided to better investigate. During FFR measurements, the mere 
presence of the GC in the coronary ostium induces some degree of stenosis, 
which depends on the relative size of the GC and the coronary ostium. This 
results into a not fully hyperemic flow across the ostium, with an artificial 
decrease of the mean aortic pressure (Pa) and a final overestimation of FFR 
value. In the DISENGAGE registry (chapter 11) we observed that GC 
disengagement is associated with: (a) slight albeit non-significant decrease 
in FFR values overall, mainly due to an increase of the mean Pa value rather 
than changes in the mean Pd value; (b) a shift from above to below the 
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clinical-decision making threshold of 0.80 in 1 out of 5 FFR measurements 
(in the range of 0.81-0.85 stratum), with a significant impact on treatment 
strategy; (3) a significant difference from the intrinsic variability of repeated 
FFR measurements in 50% of the stenoses (cut-off test-retest repeatability 
0.02); and (4) a significant impact of the epicardial stenoses location on the 
FFR measurements (proximal and mid segments vs distal segments and side 
branches). Accordingly, for a proper FFR assessment, GC disengagement 
during hyperemic state has a crucial impact in order to guarantee the 
maximum flow across the coronary ostium.  
Also a “dynamic epicardial stenosis”, like the myocardial bridge (MB), might 
be a misleading setting in terms of functional assessment. Indeed in 9 
symptomatic patients with MB and without significant CAD we aimed to 
evaluate the hemodynamic effect of physiological exercise (supine bicycle 
set during coronary angiography) on Pd/Pa, end-diastolic Pd/Pa and FFR. 
According to our results, invasive hemodynamic evaluation of MB might be 
better assessed with FFR at rest (chapter 12).  
Due to the increasing confidence of the interventional cardiologists, FFR 
guidance is also being implemented to indicate or guide CABG. However 
recommendations for FFR adoption were based on RCTs investigating PCI 
strategies in which patients with typical indications for CABG were excluded 
(e.g. LM disease, valvular disease, and coronary anatomy unsuitable for 
PCI). In a sub-analysis of the GRAFFITI trial, a single-blinded, open-label, 
prospective 1:1 randomized controlled multi-center pilot trial comparing 
FFR-guided versus angiography-guided CABG, among the 88 patients 
randomized to FFR-guided strategy, the disclosure of FFR has changed 
bypass strategy in 55% of the patients, significantly simplifying the surgical 
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protocol. At 1-year follow-up, outcomes were similar between patients with 
at least 1 change in strategy according to FFR and patient without any 
change in therapeutic decision (chapter 14). Our results confirm that FFR 
can play an important role in risk stratification and determining 
management strategy of patients either before or after CABG, without any 
untoward hazard on 1-year clinical outcome. 
Other settings in which FFR assessment is becoming more attractive, and 
for which there is a lack of evidence from RCTs are: valvular heart disesases, 
especially AS, and patients with LVD and/or HF. In patients with  AS 
myocardial ischemia can be related to several factors than the mere 
epicardial stenosis. Some relate to left ventricular hypertrophy, others to 
the hemodynamic alterations associated with aortic valve disease. 
Therefore even in the presence of normal epicardial conductance, ischemia 
could be present in some AS patients. By matching 106 patients with AS and 
CAD treated according to FFR values, with 212 contemporary control 
patients with AS in which revascularization was decided on angiography 
only, we have founded a downgrading of the CAD severity in the FFR-guided 
group and resulted into more PCI. FFR evaluation in patients undergoing 
surgery was also associated with less venous grafts and anastomoses, yet 
without higher event rates up to 5 years of follow-up (chapter 15 and 16). 
In 1,676 stenoses from patients affected by various degrees of HF of 
different etiologies we investigated whether incorporating the value of 
right atrial pressure into the FFR formula has any clinical impact on FFR 
measurement. Although these patients had a Pra often markedly above the 
normal range, the agreement between measured FFR and calculated FFRmyo 
was excellent, with a difference as minimal as 0.01. In a small fraction of 
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patients (9%), the FFR value went from >0.80 to an FFRmyo value of ≤0.80, 
with an individual difference of no more than 0.03 and in no case did an FFR 
value >0.80 yield an FFRmyo <0.75 (chapter 17). This observed difference 
between the 2 values is still within the range of test–retest repeatability of 
FFR measurements. Considering the negligible impact of right atrial 
pressure on FFR measurement we subsequently evaluated, in patients with 
non-valvular LVD and CAD, the impact of FFR on: reclassification of stenosis 
significance; indication to revascularization; revascularization strategy; 
long-term clinical follow-up. After hemodynamic assessment, the number 
of stenotic vessels per patient was significantly downgraded within the FFR-
guided group (433 patients), with a significantly lower revascularization rate 
as compared with the angio-guided group (866 patients). PCI was 
performed more frequently in the FFR-guided group (36% vs. 28% in the 
angio-guided group; p<0.01); while CABG was more often the therapy of 
choice in the angio-guided group (32% vs. 16% in the FFR-guided group, 
p<0.01). At 5-year follow-up, FFR was associated with lower MACCE and 
mortality rates and safer deferral of patients towards medical therapy as 
compared with an angio-guided strategy (chapter 18). Accordingly, FFR has 
the ability to discriminate patients who can benefit the most from surgical 
revascularization and to safely refer or defer other patients to less invasive 
treatment (PCI or OMT). In fact, the beneficial effect of FFR on clinical 
outcomes seems more evident in patients with severely reduced systolic 
function (EF ≤35%), likely presenting with many comorbidities and higher 
surgical risk. 
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Part IV. Angiography-derived FFR technologies 
Despite its clear advantages, the clinical adoption of FFR has been variable 
and slow for several reasons widely discussed in the introduction 
paragraph(18,19). A tool that allows calculating FFR without the use of costly 
pressure wires and the administration of adenosine could increase the 
adoption of FFR. Several image-based FFR methodologies have recently 
been introduced. Computational fluid dynamics (CFD) simulation applied to 
cardiac computed tomographic images and to flat detector angiograms for 
the evaluation of noninvasive FFR have been proposed(55-59). However, the 
computational complexity of such simulations requires manual interaction 
and considerable processing time, which limits the application of these 
approaches in clinical practice. During the last 3 years we have carried out 
validation studies of FFRangio and QFR, two new angiography derived-FFR 
technologies, not based on CFD, that are gaining interest in interventional 
cardiology practice. QFR (developed by Medis Medical Imaging System, 
Leiden, the Netherlands), based on a patient-specific flow by frame count 
analysis, showed a good agreement with the invasive standard FFR 
measurements, which was particularly favorable with QFR derived from 
contrast-flow (cQFR) and adenosine-flow models (aQFR). The diagnostic 
accuracy of all 3 QFR approaches for predicting an FFR of ≤0.80 was 
relatively high, ranging from 80% for QFR by the fixed-flow model (fQFR), to 
86% and 87% for cQFR and aQFR models. Nevertheless, the diagnostic 
accuracy of the simplified fQFR computation is suboptimal, with a positive 
likelihood ratio of 4.8 which implies that this approach is not of sufficient 
diagnostic value to be clinically useful. In contrast, the transport time of the 
contrast medium can be used for a patient-specific estimation of coronary 
flow, which might improve FFR computation, as previously shown(60). 
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However, aQFR unexpectedly did not further improve the FFR estimation, 
compared with cQFR. Of note, good correlation and agreement between 
cQFR and aQFR was observed. FFRangio (developed by CathWorks, Ltd) 
provides a 3D functional angiography mapping of the coronary tree with 
superimposed, color-coded, FFR values. Stated another way, FFRangio 
displays a functional angiogram. This computational method is based on a 
rapid flow analysis after a classification of the dynamic characteristics of the 
vessels in conjunction with the patient’s hemodynamic information, 
allowing to assess FFR using routine angiograms within a few minutes of 
automatic processing. All stenoses are converted into resistances in a 
lumped model, whereas scaling laws(61-63) are used to estimate the 
microcirculatory bed resistance. In our validation study  FFRangio achieved a 
diagnostic accuracy of 93%. Importantly, the fact that 67% of the lesions 
analyzed had invasive FFR values of 0.70 to 0.90, and 35% of the lesions had 
invasive FFR values between 0.75 and 0.85, that is, adjacent to the cutoff 
value, proves a high diagnostic accuracy for the entire clinically relevant 
range and not only in extreme cases. Moreover, a low interobserver 
variability was demonstrated for the FFRangio system. To achieve a routine 
adoption of FFRangio and QFR in the daily practice in cahtlab, at least 3 
conditions should be met. First, data acquisition should minimally disrupt 
routine angiography. Both technologies only requires the acquisition of 2 to 
3 conventional radiographic projections, in which the lesions can be clearly 
delineated. Care should be taken to visualize the entire coronary tree on 
the screen and to optimize filling. There is no need for vasodilation, nor any 
approximation of coronary flow. The images should be of high resolution, 
with a frame rate of at least 10 frames per second; all these parameters are 
routinely available in modern catheterization suites. Second, the processing 
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time should be as short as possible. In both validation studies performed, 
this aspect could not be quantified because the FFRangio and QFR processing 
were performed offline to ensure the blinding of the operators. Third, the 
process should be as much operator independent as possible. The present 
versions of the FFRangio and QFR technologies require minimal user guidance 
in the flow calculation process. This is translated into a low interoperator 
variability. In addition, it seems desirable to provide the physician with a full 
physiological roadmap, rather than only single-vessel segments. Once such 
a complete physiological roadmap is derived from the classical angiogram 
and simultaneously displayed next to it, anatomy and function can be easily 
integrated into the clinical decision-making process. 
 
Part V. Platelet and microvascular function 
An increased platelet reactivity (PR) associated with variable degree of 
coronary microvascular impairment has been reported after elective PCI, 
despite pretreatment with aspirin and clopidogrel(64,65). Coronary vessel 
manipulation especially during complex PCI is an additional trigger for 
transient increase in PR(66), which could favor a thrombotic milieu 
portending distal embolization(67). Considering the strong platelet inhibition 
of prasugrel, we compared in the PROMICRO 2 trial the effects of prasugrel 
vs. clopidogrel on PR and the PCI-induced coronary microvascular 
impairment.  We observed a significant peri-procedural increase in PR in 
the clopidogrel group (p=0.008), but not in the prasugrel group (p=0.822), 
with a significant correlation between IMR and PR both at baseline 
(r=0.458, p=0.003) and post-PCI (r=0.487, p=0.001) (chapter 23 and 24). Our 
result (1) corroborate the suboptimal platelet inhibition of clopidogrel in a 
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substantial proportion of patients, with subsequent increased risk of 
ischemic events(64,65) and (2) suggest that a correlation exists between 
residual PR and coronary microvascular resistance. Therefore, the 
protective effect of a loading dose of prasugrel provide more potent 
platelet inhibition, which may be of particular benefit when extensive 
intracoronary manipulation in some PCI setting is expected. However, 
clopidogrel is still the antiplatelet agent of choice in patients with stable 
CAD undergoing elective PCI. Several studies have also demonstrated that 
the increased PR is proportional to the extent of vascular damage induced 
by the coronary intervention and to the length of the stent implanted, 
translating into PMI(66,68,69). In PROACTIVE trial we compared the BVS 
Absorb™ with EES Xience™ in the setting of long coronary lesions, in order 
to evaluate if BVS implantation may acutely affect the coronary 
microvasculature with potential effect on the related platelet activation and 
peri-procedural myonecrosis. We found a significant reduction of cIMR 
after PCI in the BVS group but not in the EES group (p= 0,04), therefore 
meeting the primary endpoint of significant between groups difference in 
ΔcIMR, in favor of the BVS group (p= 0,04). In addition, we observed a 
significant PR reduction after PCI with both EES and BVS implantation, 
without differences between the two groups at baseline, post-PCI and at 30 
days follow-up. Also no difference in PR over time up to 30 days follow-up 
has been detected. Last, peri-procedural myonecrosis after PCI of long 
coronary lesions was important with both BVS and EES, without significant 
variations in terms of ∆hs-cTnT between the two groups. In designing the 
present randomised trial, the assumption was made that the metallic DES is 
associated with an increased compliance at the two contiguous segments of 
the stent implanted, generating a compliance mismatch. This translates into 
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important ring vortices at the in-flow of the stent and rapid variations of 
wall shear stress that might potentially induce platelet activation and 
thrombus formation(70). The significant reduction of cIMR after BVS 
implantation might seem at odds with the available data in the literature 
suggesting increased thrombogenicity. To achieve a similar radial strength 
to that of an 80 µm metallic stent, the PLLA backbone of the 150 µm 
everolimus-eluting BVS is designed to have both thicker and wider struts (71-
73). This translates on one hand into a significantly increased surface of 
contact between the BVS and vessel wall compared to second and third 
generation DES(74-76), but on the  other hand, the increased strut thickness 
and width have been associated with more thrombogenicity in animal 
models(77), also explaining the increased thrombogenicity of BVS in 
comparison with EES(78,79). How does our finding reconcile with these 
evidences? We can assume that the lower microvascular impairment after 
BVS implantation is due to two main reasons: (1) as compared with EES 
implantation, the scaffold deployment is associated with a greater 
retention of athero-thrombotic debris from the coronary plaques 
preventing their embolization distally in the microcirculation; (2) The 
potential increased thrombogenicity of BVS is compensated by a lower 
compliance mismatch, with a final neutral impact on the microvasculature. 
BVS implantation is not associated with an increase in compliance at the 
inflow segment, but conversely tended to decrease compliance at the 
outflow segment, therefore resulting into a potentially lower degree of 
compliance mismatch(70). The significant reduction in platelet reactivity with 
both BVS and EES is another interesting finding of the PROACTIVE trial. The 
significant reduction of hs-ADP in both groups, in fact, without differences 
at baseline, post-PCI and 30 days follow-up, confirm the results of previous 
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studies supporting that in patients with adequate response to DAPT, 
thrombogenicity of BVS Absorb™ is not affected by on-treatment platelet 
reactivity but is mainly due to a suboptimal vessel sizing and procedural 
technique at the time of its implantation(80,81). In our trial the discrepancy 
between the reduction of cIMR and the significant increase of hs-cTnT after 
BVS implantation could be explained by the fact that, although the BVS 
implantation is associated with an high retention of atherothrombotic 
debris, because of thicker wider struts as compared with DES, is also related 
to an important rate of small side branches occlusion. Our results are in line 
with a post-hoc analysis of the ABSORB II trial, where no differences in the 
incidence of cardiac biomarker rise and PMI were found between the two 
groups (82). 
 
Part VI. Percutaneous coronary interventions in bifurcation lesions: from 
bench tests to clinical outcome 
According to different calculations and observations, nearly 10% to 15% of 
all PCI procedures involve a clinically relevant bifurcation stenosis(83,84). 
Although provisional T-stenting represents a good solution for simpler 
anatomies(85), the proper treatment of more complex coronary bifurcation 
lesions remains a challenge. This is mainly due to their anatomic variation in 
terms of diameters, angulations, and the involvement by atherosclerotic 
disease. Various approaches have been developed for bifurcation stenting 
using conventional stent platforms. We evaluated in 35 patients the clinical 
applicability of the single-string bifurcation stenting technique, previously 
described by Kawasaki T et al(86), and further investigated by us in detailed 
vitro analysis(87). All the cases were performed successfully, within a 
reasonable length of time and using the usual amount of contrast and 
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radiation exposure. Furthermore, postprocedural laboratory tests did not 
show clinically relevant periprocedural myocardial necrosis (chapter 28). It 
is important to emphasize that the single string technique is safe to perform 
because, in case of difficulties, the procedure can be immediately 
converted to the culotte technique (if the protrusion into the MB was 
unnecessarily long), the mini-crush technique (if the protrusion into the MB 
was too small), or T-stenting (if no protrusion into the MB was obtained at 
all). Also it appears to offer the best compromise between perfect strut 
coverage of the whole bifurcation area with minimal overlap of one single 
string of strut. Based on the principle of single string technique we sought 
to introduce a potential novel bail out strategy for provisional T-stenting, 
when the result in the SB is suboptimal and requires stenting. We therefore 
described, in 3 vitro silicone phantoms, the procedural steps of the 
Reversed Single String technique. As shown, procedure can be performed 
within a reasonable time, with acceptable radiation exposure and without 
need for much additional equipment. Analysis of the cases showed 
excellent final result with a malapposition rate lower than 15% in the area 
of the bifurcation. Although such in vitro case report does not allow direct 
comparison with other methods, the observed malapposition rate is 
promisingly low, when considering that other techniques have reported 
malapposition rates as high as 30–49%(88-92)(chapter 29). We believe that 
Reversed Single String bifurcation technique could offer a potential bail out 
solution for such clinical scenarios.  
While the behavior and performance of conventional metallic stents have 
been thoroughly investigated in vitro, as well as in vivo, our knowledge is 
still limited about bioresorbable vascular scaffolds, especially new 
technologies such as the resorbable magnesium scaffold (RMS). For the first 
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time we evaluated the RMS performance in vitro, focus on vessel tortuosity 
and bifurcations. All procedures were performed successfully with good 
result according to fluoroscopy, with an overall malapposition rate in 
bifurcation cases of 4.3%, detected by OCT, occurring predominantly in the 
carinal area. Considering that previous in vitro and in vivo studies, with 
limited sample sizes, investigating various bifurcation techniques reported 
malapposition rates in the region of bifurcation ranging between 30-45%, 
present data can be considered at least comparable, if not favourable(87,93). 
No strut fractures or major deformations were revealed by OCT. No 
relevant malapposition was seen at the proximal MB confirming the proper 
conformability of the RMS, at least in the indicated range of diameters 
(chapter 30). To summarize, performance was comparable with previous in 
vitro and in vivo experiences with conventional metallic stents in the 
literature. This finding is also aligned with the limited animal data using 
RMS in bifurcations(94). Despite such advances in stent technologies and 
adjunctive pharmacotherapies, the treatment of bifurcations is associated 
with worse outcomes when compared with simple coronary lesions(95). Also 
other areas of incertitude in PCI of bifurcation lesions derive from the 
choice of adjunctive P2Y12 inhibitor, the optimal DAPT, as well as the 
selection of the stent platform. In the “P2Y12 inhibitor utilization in 
Bifurcation and Chronic Total Occlusion percutaneous coronary 
intervention with biologically active stents (P2BiTO) registry” we aimed to 
verify the relative implication of clinical presentation, angiographic 
characteristics and treatment strategies on mid-term outcomes in 5,036 
patients who underwent PCI with either DES or BVS on coronary 
bifurcations. Older age, ACS at admission, diabetes, left ventricular 
dysfunction, SB lesion length ≥9 mm, bail-out stenting (beyond a planned 
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strategy of either single or double stenting) and use of BVS were 
independent risk factors for MACCE (chapter 31). Even considering the 
retrospective, observational design of this study, our findings emphasize 
the importance of a carefully planned strategy for complex bifurcation PCI 
in the “real world” clinical practice. 
 
 
Conclusions 
 
In this long lasting research journey we investigated: a) the prognistic role 
of FFR in functional evaluation of epicardial stenosis in different anatomical 
and clinical settings of patients with stable CAD, heart valve disease and 
LVD; b) the role of IMR, CFR and absolute coronary flow and microvascular 
resistances assessment with a new dedicated thermodilution catheter; c) 
the diagnostic performance of two new angiography-derived FFR 
technologies for a quantitative and functional assessment of CAD; d) the 
impact of antiplatelet agents and BVS Absorb™ implantantion on 
procedure-related microvascular impairment, platelet activation and the 
related myonecrosis; e) the safety and feasibility of new 2-stent bifurcation 
techniques and the clinical outcome of known bifurcations techniques. We 
believe that many answers have been provided by our extensive 
translational research. FFR remain the milestone in functional assessment 
of the ischemic burden related to coronary stenoses. Our findings 
corroborate the strong clinical outcome background of FFR, supporting FFR-
guided revascularization strategies above angio-based decision making, and 
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therefore strongly discouraging any purely anatomy guided 
revascularization attempts in different clinical and anatomical settings. 
Absolute coronary blood flow (Q) and microvascular resistance (R) can be 
safely and reproducibly measured with continuous thermodilution, opening 
new opportunities for the study of the coronary microcirculation. FFRangio 
and QFR provide both a comprehensive physiological assessment of the 
entire coronary tree within few minutes, enabling online FFR measurement 
during the angiographic procedure. This, in turn, may facilitate the adoption 
of FFR-based clinical decision making regarding coronary revascularization. 
Both prasugrel and BVS Abosrb™ have proven a beneficial acute effect on 
peri-procedural coronary microvascular function and platelet activation. 
Although BVS Absorb™ did not live up to its promise because of the higher 
events in the mid-term due to greater scaffold thrombosis, our findings are 
at least reassuring on the acute impact of these devices on the 
microcirculation. Lastly in PCI of bifurcation lesions, our feasibility results of 
in vitro tests, offer new solutions for both complex anatomy requiring 2-
stent-technique and bailout technique in case of failure of the most 
consolidated provisional T-stenting.   
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List of abbreviations 
 
CAD: coronary artery disease; 
FFR: fractional flow reserve; 
PCI: percutaneous coronary intervention; 
CFR: coronary flow reserve; 
IMR: index of microcirculatory resistance;  
Tmn: mean transit time;  
CABG: coronary artery bypass grafting; 
LVD: left ventricular dysfunction;  
HF: heart failure;  
PMI: periprocedural myocardial infarction;  
RMS: resorbable magnesium scaffold;  
RCT: randomized clinical trial; 
RCA: right coronary artery; 
LCA: left coronary artery; 
IC: intracoronary; 
TTE: transthoracic echocardiography; 
IV: intravenous;  
MI: myocardial infarction;  
VE: visual estimation; 
QCA: quantitative coronary angiography;  
RF: risk factors;  
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DS: diameter stenosis; 
VOCE: vessel-oriented clinical end point; 
GC: guiding catheter;  
ACS: acute coronary syndrome; 
STEMI: ST-segment elevation myocardial infarction;  
NSTEMI: non-ST segment elevation myocardial infarction; 
MB: Myocardial Bridge; 
SVG: saphenous vein graft; 
AS: aortic stenosis;  
AVR: aortic valve replacement; 
MACE: major adverse cardiac events; 
MT: medical therapy; 
DES: drug-eluting stent;  
LVEF: left ventricular ejection fraction; 
MACCE: major adverse cardiovascular and cerebrovascular events; 
LM: left main; 
QFR: quantitative flow ratio; 
3D: 3-dimensional;  
DICOM: Digital Imaging and Communications in Medicine; 
CFD: computational fluid dynamic; 
PR: platelet reactivity; 
hs-TnT: High-sensitivity troponin T; 
NO: Nitric oxide; 
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ARU: aspirin reactivity unit; 
PRU: P2Y12 reactivity unit; 
DAPT: dual antiplatelet therapy; 
sUA: serum uric acid;  
BVS: Bioresorbable vascular scaffold; 
PLLA: poly-L-lactic acid; 
EES: everolimus-eluting stent; 
cIMR: corrected index of microvascular resistance;  
hs-ADP: high-sensitivity adenosine diphosphate; 
SB: side branch; 
MB: main branch; 
OCT: optical coherence tomography; 
OFDI: Optical frequency domain imaging; 
μCT: micro-computed tomography;  
OMT: optimal medical therapy; 
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